MXPA06004883A - Use of thienopyrimidines - Google Patents

Abstract

The invention relates to compounds of formula (I), wherein R1, R2, R3, R4, X and n have the meanings cited in claim (1). Said compounds are inhibitors of tyrosinkinases, especially TIE-2, and Raf- Kinases and can be used, for example, in the treatment of tumours.

Description

USE OF TIENOPIRIMIDINES FIELD OF THE INVENTION The invention aims to find novel compounds and / or novel uses of compounds having valuable properties, in particular those that can be used for the preparation of medicaments. The present invention relates to compounds and the use of compounds in which the inhibition, regulation and / or modulation of kinase signal transduction, in particular transduction of the tyrosine kinase and / or serine / threonine kinase signal, plays a role. paper, in addition to pharmaceutical compositions which comprise those compounds, and the use of the compounds for the treatment of diseases induced by tyrosine kinase. Specifically, the present invention with compounds and the use of compounds which inhibit, regulate and / or modulate the tyrosine kinase signal transduction, with compositions which comprise those compounds, and with methods for the use thereof for the treatment of diseases and conditions induced by tyrosine kinase, such as angiogenesis, cancer, tumor formation, growth and spread of tumors, atherosclerosis, eye diseases, such as age-induced macular degeneration, choroidal neovescularization and retinopathy FDD: 171522 diabetic, inflammatory diseases, arthritis, thrombosis, fibrosis, glomerulonephritis, neurodegeneration, psoriasis, restenosis, wound healing, rejection of transplant, metabolic disorders and diseases of the immune system, also autoimmune diseases, cirrhosis, diabetes and diseases of blood vessels, including instability and permeability, and the like, in mam íferos. BACKGROUND OF THE INVENTION Tyrosine kinases are a class of enzymes with at least 400 members which catalyze the transfer of the terminal phosphate of adenosine triphosphate (gamma-phosphate) to tyrosine residues on protein substrates. It is thought that tyrosine kinases, through phosphorylation of the substrate, play a crucial role in signal transduction for a number of cellular functions. Although the precise mechanisms of signal transduction are not yet clear, tyrosine kinases have been shown to be important contributing factors in cell proliferation, carcinogenesis, and cell differentiation. Tyrosine kinases can be categorized as receptor-type tyrosine kinases or as non-receptor tyrosine kinases. Tyrosine receptor kinases have an extracellular portion with a transmembrane portion and an intracellular portion, while non-receptor tyrosine kinases are exclusively intracellular (see reviews by Schlessinger and Ullricch, Neuron 9, 383-391 (1992) and 1- 20 (1992)). Tyrosine kinases type receptor consist of a multiplicity of transmembrane receptors with different biological activity. Thus, approximately 20 different subfamilies of receptor tyrosine kinases have been identified. A subfamily of tyrosine kinases, known as the HER subfamily, consists of EGFR, HER2, HER3 and HER4. Ligands of this subfamily of receptors include epithelial growth factor, TGF-, amphiregulin, HB-EGF, betacellulin and heregulin. Another subfamily of these type receptor tyrosine kinases is the insulin subfamily, which includes INS-R, IGF-IR and IR-R. The PDGF subfamily includes the receptors of PDGF-, and -ß, CSFIR, c-kit and FLK-II. In addition, there is the FLK family, which consists of the kinase insert domain (KDR) receptor, fetal liver kinase -1 (FLK-1), fetal liver kinase-4 (FLK-4) and tyrosine kinase-1 fms (flt-1). The PDGF and FLK families are usually discussed together due to the similarities of the two groups. For a detailed discussion of receptor tyrosine kinases, see the article by Plowman et al., DN & P 7 (6): 334-339, 1994, which is incorporated herein by reference. RTKs (receptor-type tyrosine kinases) also include TIE2 and its angiopoietins ligands 1 and 2. More homologs of these ligands have now been found., the action of which has not yet been clearly demonstrated in detail. TIE1 is known as a TIE2 counterpart. TIE RTKs are selectively expressed on endothelial cells and are involved in processes of angiogenesis and maturation of blood vessels. They can therefore be a valuable objective, in particular, in diseases of the vascular system and in pathologies in which the vessels are used or even reformed. In addition to the prevention of neovascularization and maturation, the stimulation of neovascularization may also be a primary objective for active compounds. Reference articles on angiogenesis, tumor development and kinase signal transduction are referred to by G. Breier Placenta (2000) 21, Suppl A, Trophoblasr Res 14, S11-S15 F. Bussolino et al. TIBS 22, 521-256 (1997) G. Bergers S_ L.E. Benjamin Nature Rev Cancer 3,401-410 P. Blume-Jensen & amp; amp; amp; amp;; Hunter Nature 411, 355-365 (2001) M. Ramsauer & P. D'Amore J. Clin. INvest. 110, 1615-1617 (2002) S. Tsigkos et al. Expert Opin. Investig. Drugs 12, 933-941 (2003) Examples of kinase inhibitors that have already been tested in cancer therapy are given in L.K. Schawyer et al Cancer Cell 1, 117-123 (2002) and D. Favor & C Garcia-Echecerria Current Opin. Drug Discovery & Development 5,701-712 (2002). Non-receptor type tyrosine kinases likewise consist of a multiplicity of subfamilies including Src, Rfk, Btk, Csk, Abl, Zap70, Fes / Fps, Fak, Jak, Ack, and LIMK. Each of these subfamilies is further subdivided into different receptors. For example, the Src subfamily is one of the largest families. This includes Src, Yes, Fyn, Lck, Blk, Hck, Fgr and Yrk. The Src enzyme subfamilies have been linked to oncogenesis. For a more detailed discussion of non-receptor tyrosine kinases, see the article by Bolen Oncogene, 8: 2025-2031 (1993), which is therefore incorporated by reference. Both receptor type tyrosine kinases and non-receptor tyrosine kinases are involved in cell signaling pathways leading to various pathogenic conditions, including cancer, psoriases and hyperimmune responses. It has been proposed that several receptor-type tyrosine kinases, and the growth factors to which they bind, play a role in angiogenesis, although some may indirectly promote angiogenesis (mustonen and Alitalo, J. Cell Biol. 129: 895-898, nineteen ninety five). One of these receptor-type tyrosine kinases is the fetal liver kinase 1 also known as FLK-1. The human analogue of FLK-1 is a receptor containing domain of the KDR kinase insert, which is also known as vascular endothelial cell growth factor 2 receptor or VEGFR-2, since it binds to VEGF with high affinity. Finally, the murine affinity of this receptor has also been called NYK (Oelrichs et al., Oncogene 8 (1): 11-15, 1993) VEGF and KDR are a pair of ligand-receptor that plays a vital role in proliferation of vascular endothelial cells and the formation and outbreak of blood vessels, known as vasculogenesis and angiogenesis respectively. Angiogenesis is characterized by excessive activity of vascular endothelial growth factor (VEGF). VEGF actually consists of a family of ligands (Klags burn and D'Amore, Cytokine &Growth Factor Reviews 7: 259-270, 1996.). VEGF binds to the tyrosine kinase receptor qxie encompassing the high affinity membrane KDR and the related tyrosine kinase Flt-1, also known as Flt-1 or receptor and vascular endothelial cell growth factor 1 (VEGFR-1). Cell culture and genetic alteration experiments indicate that each receptor contributes to different aspects of angiogenesis. KDR mediates the photogenic function of VEGF, whereas Flt-1 seems to modulate non-mitogenic functions as those associated with cell adhesion. The inhibition of KDR in this way modulates the level of mitogenic activity of VEGF. Indeed, it has been shown that tumor growth is susceptible to the angiogenic effect of VEGF receptor antagonist (Kim et al Nature 362, pp. 841-844, 1993). Three PTK receivers have been identified (protein tyrosine kinase) for VEGFR: VEGFR-1 (Flt-1); VEGRF-2 (Flk-1 or KDR) and VEGFR-3 (Flt-4). VEGGFR-2 is of particular interest. Solid tumors can therefore be treated with tyrosine kinase inhibitors since these tumors depend on angiogenesis for the formation of the blood vessels that are necessary to support their growth. These solid tumors include monocytic leukemia, brain carcinoma, urogenital tract, lymphatic system, stomach, larynx and lung, including pulmonary adenocarcinoma and small cell lung carcinoma. Additional examples include carcinomas in which overexpression or activation of Raf activating oncogenesis is observed (e.g., K-ras, erb-B). These carcinomas include pancreatic and breast carcinoma. Inhibitors of these tyrosine kinases are therefore suitable for the prevention and treatment of proliferative diseases caused by these enzymes. The angiogenic activity of VEGF is not limited to tumors. VEGF contributes to the angiogenic activity produced in or near the retina in diabetic retinopathy. This vascular growth in the retina leads to visual degeneration that culminates in blindness. Ocular VEGF mRNA and protein levels are elevated by conditions such as retinal vein occlusion in primates and decreasing the level of p02 in mice, which leads to neovascularization. Intraocular injections of anti-VEGF monoclonal antibodies or VEGF receptor immunoinfusions inhibit ocular neovascularization in models with primates and rodents. Regardless of the cause of the induction of VEGF in human diabetic retinopathy, the inhibition of ocular VEGF is adequate to treat this disease. The expression of VEGF also increases significantly in hypoxic regions of tumors of animals adjacent to areas of necrosis. In addition, VEGF is upregulated by the expression of the oncogenes flush, raf, src and p53 mutants (all of which are important to fight cancer). Anti-VEGF monoclonal antibodies inhibit the growth of human tumors in hairless mice. Although these same tumor cells continue to express VEGF in culture, the antibodies do not decrease their mitotic rate. Thus, tumor-derived VEGF does not function as an autogenous mitogenic factor. VEGF therefore contributes to the growth of tumors in vivo by promoting angiogenesis through its chemotactic and mitogenic cellular endothelial vascular paracrine activities. These monoclonal antibodies also inhibit the growth of human colon carcinomas typically vascularized in athymic mice and decrease the number of tumors arising from inoculated cells. Expression of a VEGF binding construct of Flk-1, Flt-1, the homolog of the truncated mouse KDR receptor to eliminate cytoplasmic tyrosine kinase domains but retain a membrane anchorage, in virus, virtually retains the growth of a glioblastoma transplantable in mice, presumably because of the dominant negative mechanism of heterodimer formation with the endothelial cellular VEGF receptors that span the membrane. Undifferentiated embryonic cells, which normally grow as solid tumors in hairless mice, do not produce detectable tumors if both alleles of VEGF are altered. Taken together, these data indicate the role of VEGF in the growth of solid tumors. Inhibition of KDR or Flt-1 is involved in pathological angiogenesis, and those receptors are suitable for the treatment of diseases in which angiogenesis is part of the total pathology, for example inflammation, diabetic retinal vascularization, as well as various forms of cancer, since it is known that tumor growth depends on angiogenesis (Weidner et al., N. Engl.

J. Med., 324, pp. 1-8, 1991). Angiopoietin 1 (Angl), a ligand for TIE-2 endothelium-specific receptor-type tyrosine kinase, is a novel angiogenic factor (Davis et al, Cell, 1996, 87: 1161-1169; Partanen et al, Mol. Cell Biol., 12: 1698-1707 (1992); U.S. Patent No. 5,521,073; 5,879,672; 5,877,020; and 6,030,831). The acronym TIE stands for "tyrosine kinase with homology domains of Ig and EGF". TIE is used for the identification of a class of receptor tyrosine kinases which are expressed exclusively in vascular endothelial cells and primitive hematopoietic cells. TIE receptor kinases are typically characterized by the presence of a VEGF-like domain and an immunoglobulin-like domain (Ig) which consists of extracellular pleated units stabilized by disulfide bridge bonds between the chains (Partanen et al., Topics Microbiol. Immunol., 1999, 237: 159-172). In contrast to the VEGF, which exerts its function during the initial stages of vascular development, the Angl and its receptor TIE-2 act during the last stages of vascular development, that is, during vascular transformation (the transformation is related to the formation of a vascular lumen) and maturation (Yancopoulos et al, Celi, 1998, 93: 661-664, Peters, KG, Circ Res., 1998, 83 (3): 342-3; Suri et al, Cell 87, 1171-1180 (1996)).

Consequently, it would be expected that the inhibition of TIE-2 would interrupt the transformation and maturation of a new vascular system initiated by angiogenesis and should thus interrupt the process of angiogenesis. In addition, inhibition at the binding site of the kinase domain of VEGFR-2 would block the phosphorylation of the tyrosine residues and serve to interrupt the onset of angiogenesis. Therefore, it should be assumed that the inhibition of TIE-2 and / or VEGFR-2 should prevent tumor angiogenesis and serve to obtain or completely eliminate tumor growth. Accordingly, treatment of cancer and other diseases associated with inappropriate angiogenesis could be provided. The present invention is directed to methods for the regulation, modulation or inhibition of TIE-2 for the prevention and / or treatment of diseases associated with the unregulated or disrupted activity of TIE-2. In particular, the compounds of formula I can also be used in the treatment of certain forms of cancer. In addition, the compounds of formula I may also be used to provide additive or synergistic effects in certain existing cancer chemotherapies and / or may be used to restore the efficacy of certain existing cancer chemotherapies and radiotherapies.

The compounds of formula I can also be used for the isolation and investigation of the activity or expression of TIE-2. In addition, they are particularly suitable for use in diagnostic methods for diseases associated with the unregulated or disrupted activity of TIE-2. The present invention is directed to methods for the regulation, modulation or inhibition of VEGFR-2 for the prevention and / or treatment of diseases associated with the unregulated or disrupted activity of VEGFR-2. The present invention also relates to compounds of formula I as inhibitors of Raf kinases. Phosphorylation of the protein is a fundamental process for the regulation of cellular functions. The coordinated action of both protein kinases and phosphatase controls the degrees of phosphorylation and, consequently, the activity of specific target proteins. One of the predominant roles of protein phosphorylation is signal transduction, where extracellular signals are amplified and propagated by a cascade of protein phosphorylation and dephosphorylation events, for example, the p21ras / Raf pathway. The p21ras gene was discovered as an oncogene of the rat sarcoma viruses of Harvey (H-Ras) and Kirsten (K-Ras). In humans, characteristic mutations in the cellular Ras gene (c-Ras) have been associated with many different types of cancer. These mutant alleles, which become constitutively active Ras, have been shown to transform the cell, such as the murine cell line NIH 3T3, in culture. The p2lras oncogene is a major contributor to the development and progression of human solid carcinomas and is stimulated in 30% of all human carcinomas (Bolton et al. (1994) Ann. Rep. Med. Chem., 29, 165-74; Bos. (1989) Cancer Res., 49, 4682-9). In its normal, non-mutant form, the Ras protein is a key element of the signal transduction cascade directed by growth factor receptors in almost all tissues (Avruch et al. (1994) Trends Biochem. Sci., 19, 279-83). Biochemically, Ras "is a guanine nucleotide binding protein, and the cyclization between activated GTP-linked and the bound-to-GDP bound form is strictly controlled by the endogenous GTPase activity of Ras and other regulatory proteins. binds guanine triphosphate (GTP) and guanine diphosphate (GDP) and hydrolyzes GTP and GDP.Ras is active in the GTP-linked state.In Ras mutants in cancer cells, the endogenous GTPase activity is reduced and the protein consequently transmits constitutive growth signals to effectors in the 3 'direction, as for example, to the enzyme Ras kinase. This leads to the cancerous growth of cells containing these mutants (Magnuson et al. (1994) Semin. Cancer Biol., 5, 247-53). The proto-oncogene Ras requires a functionally intact C-Raf-1 oncogene to transduce signals of growth and differentiation initiated by tyrosine kinase of the receptor type and non-receptor type in higher eukaryotes. The activated Ras is necessary for the activation of the proto oncogene C-Raf-1, but the biochemical steps through which the Ras activates the protein kinase Raf-1 (Ser / Thr) are now well characterized. It has been shown that inhibition of the effect of active Ras by inhibiting the Ras kinase signaling pathway by the administration of antibody to those activators to Raf kinase or by the coexpression of dominant negative Raf kinase or dominant negative MEK (MAPKK), the Raf kinase substrate, leads to the reversal of transformed cells to the phenotype of normal growth, see: Daum et al. (1994) Trends Biochem. Sci., 19, 474-80; Fridman et al. (1994) J Biol. Chem., 269, 30105-8. Koich et al. (1991) Nature, 349, 426-28) and for a review Weinstein-Oppenheimer et al. Pharm. & Therap. (2000), 88, 229-279. Similarly, inhibition of Raf kinase (by antisense oligodeoxynucleotides) has been correlated with inhibition in vitro and in vivo of the growth of a variety of human tumor types (Monia et al., Nat. Med. 1996, 2, 668 -75).

The serine and threonine-specific Raf protein kinases are cytosolic enzymes that stimulate cell growth in a variety of cellular systems (Rapp, U. R., et al. (1988) in The Oncogene Handbook; T. Curran, E.P. Reddy and A. Skalka (eds.) Elsevier Science Publishers; The Netherlands, pp. 213-253; Rapp, U.R., et al. (1988) Cold Spring Harbor Sym. Quant. Biol. 53-.173-184; Rapp U.R., et al. (1990) Inv Curr. Top. Microbiol. Immnuol. Potter and Melchers (eds.), Berlin, Springer-Verlag 166: 129-139). Three isozymes have been characterized: C-Raf (Raf-1) (Bonner, T. 1., et al. (1986) Nucleic Acids Res. 14: 1009-1015). A-Raf (Beck, TW / et al. (1987) Nucieic Acids Res. 15: 595-609), and B-Raf (Qkawa, S., et al. (1998) Mol. Cell. Biol. 8: 2651 -2654; Sithanandam, G. et al. (1990) Oncogene: 1775). These enzymes differ in their expression in various tissues. Raf-1 is expressed in all organs and in all cell lines that have been examined, and A- and B-Raf are expressed in urogenital and cerebral tissues, respectively (Storm, SM (1990) Oncogene 5: 345-351) . The Raf genes are proto-oncogenes: they can initiate the malignant transformation of cells when they are expressed in specifically altered forms. The genetic changes that lead to oncogenic activation generate a constitutively active protein kinase by removal or interference with an N-terminal negative regulatory domain of the protein (Heidecker, G., et al (1990) Mol. Celi. Biol. : 2503-2512; Rapp, UR, et al. (1987) in Oncogenes and Cancer; SA Aaronson, J. Bishop, T. Sugimura, M. Terada, K. Toyoshima and PK Vogt (eds.) Japan Scientific Press, Tokyo ). Microinjection in NIH 3T3 cells from oncogenically activated, but not natural versions, and the Raf protein prepared with Escherichia coli expression vectors results in morphological transformation and stimulates DNA synthesis (Rapp, UR, et al. (1987) in Oncogenes and Cancer; SA Aaronson, J. Bishop, T. Sugimura, M. Terada, K. Toyoshima, and PK Vogt (eds.) Japan Scientific Press, Tokyo; Smith, MR, et al. (1990) Mol. Celi Biol. 10-3828-3833). Consequently, activated Raf-1 is an intracellular activator of cell growth. The protein serine kinase Raf-1 is a candidate for the effector downstream of the mitogenic signal transduction, since the Raf oncogenes overcome the growth arrest resulting from a blockage of cellular Raf activity due to a cellular mutation ( Cells that revert to Ras) or microinjection of anti-Ras antibodies (Rapp, UR, et al. (1988) in The Oncogene Handbook, T. Curran, E.P. Reddy and A.

Skalka (eds.), Elsevier Science Publishers; The Netherlands, pp. 213253; Smith, M.R. , et al. (1986) Nature (London) 320: 540-543).

The function of C-Raf required for transformation by a variety of oncogenes bound to the membrane and for the stimulation of growth by mitogens contained in the serum (Smith, MR, et al. (1986) Nature (London) 320: 540- 543). The activity of the serine protein kinase Raf-1 is regulated by mitogens via phosphorylation (Morrison, DK, et al (1989) Cell 58: 648-657), which also affects cell distribution (Olah, Z., et. al. (1991) Exp. Brain Res. 84: 403; Rapp, UR, et al. (1988) Cold Spring Harbor Sym. Quant. Biol. 53: 173-184). Activating growth factors of Raf-1 include platelet-derived growth factor (PDGF) (Morrison, DK, et al. (1988) Proc. Nati, Acad. Sci. USA 85: 8855-8859), stimulating factor from the colony (Baccarini, M., et al (1990) EMBO J. 9: 3649-3657), insulin (Blackshear, PJ, et al (1990) J. Biol. Chem. 265: 12115-12118), epidermal growth factor (EGF) (Morrison, RK, et al. (1988) Proc. Nati, Acad. Sci. USA 85: 8855-8859), interleukin-2 (Turner, BC, et al. (1991) Proc. Nati, Acad. Sci. USA 88: 1227) and interleukin-3 and colony stimulating factor of granulocytic macrophages (Carroll, MP, et al (1 990) J. Biol. Chem. 265: 19812-19817). After treatment of the cells with mitogen, the transiently activated serine protein Raf-1 translocates to the perimetral area of the nucleus (Olah, Z., et al. (1991) Exp. Brain Res. 84: 403; Rapp, U. R., et al. (1988) Cold Spring Harbor Sym. Quant. Biol. 53-. 173-184). Cells containing activated Raf are altered in their gene expression pattern (Heidecker, G., et al. (1989) in Genes and signal transduction in multistage carcinogenesis, N. Coiburn (ed.), Marcel Dekker, Inc., New York, pp. 339-374) and the Raf shrink activates the transcription of Ap-1 / PEA3-dependent promoters in transient transfection assays (Jamal, S., et al. (1990) Science 344: 463-466; Kaibuchi, K., et al (1989) J. Biol. Chem. 264: 20855-20858; Wasylyk, C, et al. (1989) Mol Cell. Biol. 9: 2247-2250). There are at least two independent pathways for the activation of Raf-1 by extracellular photons: one involving the majority of C kinases (KC) and a second one initiated by protein tyrosine kinases (Blackshear, PJ, et al. (1990) J Biol. Chem. 265: 12131-12134; Kovacina, KS, et al. (1990) J. Biol. Chem. 265: 12115-12118; Morrison, DK, et al. (1988) Proc. Nati. Acad. Scí USA 85-8855-8859; Siegel, JN, et al. (1990) J. Biol. Chem. 265: 18472-18480; Turner, BC, et al. (1991) Proc. Nati. Acad. Sci. USA 88: 1227). In each case, activation involves the phosphorylation of the RAf-1 protein. The phosphorylation of Raf-1 may be a consequence of. a kinase cascade amplified by autophosphorylation that can be caused entirely by autophosphorylation initiated by the binding of a putative activating ligand to the regulatory domain of Faf-1, analogous to the activation of PKC by diacylglycerol (Nishizuka, Y. (1986) Science 233: 305-312). One of the main mechanisms by which cellular regulation is effected is through the transduction of extracellular signals through the membrane, which in turn modulates the biochemical pathways within the cell. The phosphorylation of the protein represents the course by which the intracellular signals are propagated from molecule to molecule finally resulting in a cellular response. These cascades of signal transduction are highly regulated and often overlap, as is evident from the existence of many protein kinases such as phosphatases. Protein phosphorylation occurs predominantly in the serine, threonine or tyrosine residues, and the protein kinases have therefore been classified by their specificity of the phosphorylation site, ie serine / tyrosine kinases. Since phosphorylation is therefore a ubiquitous process within the cell and since cellular phenotypes are greatly influenced by the activity of those lines, it is currently believed that a large number of conditions and / or diseases are attributable to the aberrant activation of functional mutations in the molecular components in the kinase cascades. Accordingly, considerable attention has been devoted to the characterization of proteins and compounds that are capable of modulating their activity (see article: Weinstein-Oppenheimer et al., Pharma. &Therap., 2000, 88, 229-279). . BRIEF DESCRIPTION OF THE INVENTION The use of small compounds that inhibit specifically regulate and / or modulate the tyrosine kinase and / or Raf Kinase signal transduction is therefore desirable a principal objective of the present invention. It has been found that the compounds according to the invention and the salts thereof have very valuable pharmacological properties while being well tolerated. In particular, they exhibit tyrosine kinase inhibition properties. It has also been found that the compounds according to the invention are inhibitors of the Raf kinase enzyme. Since the enzyme is a downstream effector of p21r s, the inhibitors prove to be suitable in pharmaceutical compositions for use in medicine or veterinary where inhibition of the Raf kinase pathway is indicated, for example in the treatment of tumors / growth cancerous cell mediated by Raf kinase. In particular, the compounds are suitable for the treatment of solid cancers in humans and animals, for example murine cancer, since the progress of that cancer depends on the transduction cascade of Ras protein signals and is therefore susceptible to treatment by interruption of the cascade, that is, by the inhibition of the Raf kinase. Accordingly, the compound according to the invention or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by the Raf kinase pathway, especially cancer, including solid cancers, for example, carcinomas for example from the lung, pancreas, thyroid, bladder or colon), myeloid diseases (for example myeloid leukemia) or adenomas (for example villous colon adenoma), pathological angiogenesis and migration of metastatic cells. The compounds are also owed for the treatment of chronic inflammation dependent on complement activation (Niculescu et al. (2002) Immunol. Res., 24: 191-199) and immunodeficiency induced by HIV-1 (human immunodeficiency virus type 1) (Popik et al. (1998) J Virol 72: 6406- 6413). Surprisingly, it has been found that the compounds according to the invention can not interact with the signaling pathways, especially the signaling pathways described herein and preferably the signaling pathway of the Raf kinase. The compounds according to the invention preferably exhibit an advantageous biological activity which can be easily demonstrated in enzyme-based assays, for example, assays described herein. In those enzyme-based assays, the compounds according to the invention preferably exhibit and produce an inhibitory effect, which is usually documented by the ICS0 values in a suitable range, preferably in the micromolar range and more preferably in the range nanomolar As described here, those signaling pathways are relevant to various diseases. Accordingly, the compounds according to the invention are suitable for the prophylaxis and / or treatment of diseases that depend on the signaling pathways by the interaction of one or more of the signaling pathways. The present invention therefore relates to compounds according to the invention as promoters or inhibitors, preferably with inhibitors, of the signaling pathways described herein. The invention, therefore, preferably relates to compounds according to the invention as promoters or inhibitors, preferably with inhibitors, of the Raf kinase pathway. The invention therefore preferably relates to compounds according to the invention as promoters or inhibitors preferably with inhibitors of the Raf kinase. The invention is even more preferably related to compounds according to the invention, as promoters or inhibitors, preferably, inhibitors of one or more of Raf kinases selected from the group consisting of A-Raf, B-Raf and C-Raf- 1. The invention is particularly preferably related to compounds according to the invention as promoters or inhibitors, preferably with C-Raf-1 inhibitors. The present invention relates to the use of one or more compounds according to the invention in the treatment and / or prophylaxis of diseases, preferably the diseases described herein, which are caused, mediated and / or propagated by Raf kinases and in particular diseases which are caused, mediated and / or propagated by Raf kinases selected from the group consisting of A-Raf, B-Raf and C-Raf-1. The diseases discussed here are usually divided into two groups, and hyperproliferative and non-hyperproliferative diseases. In connection with this, psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases are considered as non-cancerous diseases, of which arthritis, inflammation, immunological diseases, autoimmune diseases and Immunodeficiency diseases are usually considered non-hyperproliferative diseases. In connection with this, brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, liver cancer, kidney cancer, colorectal cancer, breast cancer, head cancer, neck cancer, Oesophageal cancer, gynecological cancer, toroid cancer, lymphomas, chronic leukemia and acute leukemia are considered cancerous diseases, all of which are usually considered hyperproliferative diseases. Especially the growth of cancer cells and especially the growth of cancer cells mediated by the Raf kinase is a disease which is a target of the present invention. The present invention therefore relates to compounds according to the invention, as medicaments and / or active ingredients as medicaments in treatment and / or prophylaxis of a disease and with the use of compounds according to the invention for the preparation of a pharmaceutical agent for the treatment and / or prophylaxis of diseases as well as a method for the treatment of diseases, which comprises administering one or more compounds according to the invention to a patient in need of such administration. It can be shown that the compounds according to the invention have an antiproliferative action in vivo in a xenotransplanted tumor model. The compounds according to the invention are administered to a patient having a hyperproliferative disease, for example to inhibit tumor growth, to reduce the inflammation associated with a lymphoproliferative disease, to inhibit the rejection of transplants or neurological damage due to repair of tissues, etc. The compounds of the present invention are suitable for prophylactic or therapeutic purposes. As used herein, the term "treat" is used to refer to the prevention of diseases and the treatment of pre-existing conditions. The prevention of proliferation is achieved by the administration of the compounds according to the invention before the development of the disease as such, for example to prevent the growth of tumors, prevent metastatic growth, decrease the restenosis associated with cardiovascular surgery, etc. Alternatively, the compounds are used for the treatment of ongoing disease establishment or improving the clinical symptoms of the patient. The host or patient may belong to any mammalian species, for example a primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits horses, cows, dogs, cats, etc. Animal models are of interest for experimental investigations, providing a model for the treatment of human diseases. The susceptibility of a particular cell to treatment with the compounds according to the invention can be determined by in vitro tests. Typically, a cell culture is combined with a compound according to the invention at various concentrations for a period of time which is sufficient to allow the active agents to induce cell death or inhibit migration, usually between about 1 hour and 1 week. . In vi tro tests can be carried out using cultured cells from a biopsy sample. The viable cells that remain after the treatment are then counted. The doses vary depending on the specific compound used, the specific disease, the condition of the patient, etc. A therapeutic dose is typically considered sufficient to reduce the progression of undesirable cells in the target tissue while the viability of the patient is maintained. The treatment generally continues until a considerable reduction has occurred, for example the reduction of at least 50% in the cell burden, and may continue until essentially more undesirable cells are detected in the body. For the identification of kinase inhibitors, several test systems are available. In the flash proximity test (Sorg et al., J. of Biomolecular Screening, 2002, 7, 11-19) and in the flash plate assay, the radioactive phosphorylation of a protein or peptide is measured as a substrate with DATP. In the presence of an inhibitor compound, the decrease of a radioactive signal, or nothing or all, is detectable. In addition, homogeneous time-presumed fluorescence resonance energy transfer (HTR-FRET) and fluorescence phosphorylation (FP) technologies are suitable as assay methods (Sills et al., J. of Biomolecular Screening, 2002, 191). -214). Non-radioactive ELISA test methods use phospho-antibodies (phospho-AB) specific. Phospho-AB binds only to the phosphorylated substrate. This binding can be detected by chemiluminescence and by using a second anti-sheep antibody conjugated with peroxidase (Ross et al., 2002, Biochem J., about to be published, BJ20020786). There are many diseases associated with the regulation of cell proliferation and cell death (apoptosis) Conditions of interest include, but are not limited to, the following: the compounds according to the invention are suitable for the treatment of a variety of conditions where there is proliferation and / or migration of smooth muscle cells and / or inflammatory cells in the intimal layer of a vessel, resulting in restricted blood flow through that vessel, for example, in the case of neointimal occlusive lesions. Vascular diseases of occlusive transplantation of interest include atherosclerosis, coronary vascular disease after transplantation, vein graft stenosis, perianastomotic prosthetic restenosis, restinosis after angioplasty or replacement of stent device and the like. The compounds according to the invention are suitable as inhibitors of p38 kinase.

Heteroarylureas that inhibit p38 kinase are described in WO 02/85859. Some of the compounds of formula I are described as PDE V inhibitors in WO 98/06722. The compounds of formula I according to claim 29 are novel. DETAILED DESCRIPTION OF THE INVENTION The invention relates to the use of compounds of formula I wherein R1, R2 each, independently denote H, A, OA, alkenyl, alkynyl, N02, CF3 or Hal, R1, R2 together also denote alkylene having 3-5 C atoms, R3, R4 each independently of each other they denote H, A, OA, OH, Hal, N02, NH2, NHA or NAA ', R3, and R4 together also denote -0-CH2-CH2-, -0-CH2-0- or -0-CH2-CH2-0 -, A, A 'each, independently of each other, denote alkyl having 1 to 6 carbon atoms, where 1-5 H atoms can also be replaced by F and / or chlorine, X denotes a saturated heterocycle of 5. -7 members having 1-4 N, O and / or S atoms, linked N or C pathways, which is substituted or mono-, di- or trisubstituted by A, Hal or CF3, or morpholinyl, 4-Y- piperidin-1-yl or 4-Y-piperazin-1-yl, Y denotes H, A, OH, -CH 2 OH or -CH 2 CH 2 OH, Hal denotes F, Cl, Br or I and n denotes 0, 1, 2 or 3, and derivatives, solvates, salts and stereoisomers thereof pharmaceutically useful, including mixtures thereof in all ratios for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and / or modulation of signal transduction of kinase plays a role. The invention also relates to the use of optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. The term solvates of the compounds means adductions of inert solvent molecules on the compounds that are formed due to their mutual attraction force. Solvates are, for example, monohydrates or dihydrates or alkoxides. The term "pharmaceutically useful derivatives" means, for example, salts of the compounds according to the invention and also the so-called prodrug compounds.

The term "prodrug derivatives" means compounds of formula I that have been modified by means of, for example, alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the organism to form the effective compounds according to the invention. These also include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm. 115, 61-67 (1995). The term "effective amount" denotes the amount of a drug or a pharmaceutically active ingredient that produces in a system, animal or human tissue a biological or medical response that is sought or desired, for example, by a researcher or physician. In addition, the term "therapeutically effective amount" denotes an amount which, compared to a corresponding subject who has not received this amount, has the following consequences: Improved treatment, healing, prevention or elimination of a diseasesyndrome, condition, complication, disorder or side effects or also the reduction in the progress of a disease, complication, disorder or side effects or also the reduction in the progress of a disease, complication or disorder. The term "therapeutically effective amount" also encompasses the amounts that are effective in increasing normal physiological function. The invention also relates to the use of mixtures of compounds of formula I, for example mixtures of two distereomers, for example the ratio of 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1- 10, 1: 100 or 1: 1000. These are particularly preferred mixtures of stereoisomeric compounds. Up and down, the radicals R1, R2, R3, R4, X, L and n have the meanings indicated for formula I, unless otherwise expressly stated. A and A ', independently of each other, preferably denote alkyl having 1-6 carbon atoms. In the above formulas, the alkyl is preferably unbranched and has 1, 2, 3, 4, 5 or 6 carbon atoms, preferably 1, 2, 3, 4 or 5 C atoms, and preferably denote methyl, ethyl or propyl, in addition, preferably isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but also n-pentyl, neopentyl or isopentyl. Alkyl also denotes, for example, trifluoromethyl. The alkylene is preferably unbranched and preferably denotes propylene, butylene or pentylene. One of the radicals R1 and R2 preferably means H, while the other denotes preferably propyl or butyl, but particularly preferably ethyl or methyl. In addition, R1 and R2 also denote together preferably propylene, butylene or pentylene. Hal preferably denotes F, Cl or Br, but also I, particularly preferably F or Cl. Alkenyl preferably means vinyl, 1- or 2-propenyl, 1-butenyl, isobutenyl, sec-butenyl, preference is further given to 1-pentenyl, isopentenyl or 1-hexenyl. Alkynyl preferably means ethynyl, propyne-1-yl, additionally butyne-l-butyne-2-yl, pentyne-1-, pentyne-2- or pentyne-3-yl. The radicals R3 and R4 can be identical or different and are preferably in the 3- and 4- position of the phenyl ring. They denote each, for example, independently of each other, H, alkyl, alkoxy, hydroxyl, nitro, amino, alkylamino, such as, for example, methylamino, dialkylamino, such as, for example, dimethylamino, F, Cl, Br, or I, or together denote ethyleneoxy, methylenedioxy, or ethylenedioxy. They preferably also mean each alkoxy, such as, for example, methoxy, ethoxy or propoxy. R3, R4 denote in a particularly preferable manner H, F, methoxy, hydroxyl or together denote 3,4-methylenedioxy. The radical X is preferably 2- or 3 -furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 2-methyl-1-imidazole- l -yl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, preferably further 1,2,3-triazole-1-, -4- or -5- ilo, 1, 2, 4-triazol-l-, -3- or 5-yl, 1- or 5-tetrazolyl, l, 2,3-oxadiazol-4- or -5-yl, 1, 2, 4- oxadiazol-3- or -5-yl, 1, 3,4-thiadiazol-2- or -5-yl, 1, 2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol- 4- or -5-yl, 3- or 4-pyridazinyl or pyrazinyl, each of which is unsubstituted or mono-, di or trisubstituted by alkyl, Hal or CF3. X denotes in particular 1-, 2-, 4- or 5-imidazolyl, 2-methyl-1-imidazol-1-yl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 3 or 4 -pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, preferably further 1, 2, 3-triazol-l-, -4- or -5-yl, 1,2,4-triazole-1-, - 3 or 5-yl, 3- or 4-pyridazinyl or pyrazinyl. X also denotes morpholinyl, 4-Y-piperidin-1-yl, or 4-Y-piperazin-1-yl, where Y denotes H, A, OH, -CH20H or -CH2CH20H. Through the invention, all the radicals that occur more than once can be identical or different, that is they are independent of each other. The compounds of formula I may have one or more chiral centers and may therefore be present in various stereoisomeric forms. Formula I covers all these forms. Accordingly, the invention relates, in particular, to the use of compounds of formula I, in which at least one of the radicals has one of the preferred meanings indicated above. Some groups of preferred compounds can be expressed by the following subformulas la a Ih which form formula I and in which the radicals not designated in greater detail have the meanings indicated for formula I, but in which X denotes morpholinyl , imidazolyl or pyridinyl; in Ib R1, R2 each, independently of each other, denote H, A, OA, N02, CF3 or Hal, R3 and R4 together denote -0-CH2-CH2-, -0-CH2-0- or -0-CH2, -CH2, x denotes morpholinyl, imidazolyl or pyridinyl and n denotes 1; in R1, R2 each, independently of each other, denote H, A, OA, N02, CF3 or Hal, R3, R4 each, independently of each other, denote H, A, OA, Hal, N02, NH2, NHA or NAA ', X denotes morpholinyl, imidazolyl or pyridinyl and n denotes 1; in Id R1 and R2 together denote alkylene having 3-5 carbon atoms, R3 and R4 together denote -0-CH2-CH2-, -0-CH2-0- or -0-CH2-CH2-0, X denotes morpholinyl , imidazolyl or pyridinyl and n denotes 1; in R1 and R2 together denote alkylene having 3-5 carbon atoms, R3, R4 each, independently of one another, denote H, A, OA, Hal, N02, NH2, NHA or NAA ', X denotes morpholinyl, imidazolyl or pyridinyl and n denotes 1; in If X denotes morpholinyl, 1-, 2-, 4- or 5-imidazolyl, 2-methyl-1-imidazol-1-yl, 1-, 3-, 4- or 5-pyrazolyl, 2, 3 or 4 -pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1, 2, 3-triazol-1-, 4- or -5-yl, 1, 2,4-triazole-1 -, -3- or 5-yl, 3- or 4-pyridazinyl or pyrazinyl, in Ig X denotes morpholinyl, 1-, 2-, 4- or 5-imidazolyl, 2-methyl-1-imidazol-1-yl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1, 2, 3-triazole-1-, -4- or -5-yl, 1,2,4-triazol-l-, -3- or 5- yl, 3- or 4-pyridazinyl or pyrazinyl, R1, R2 each, independently of each other, denote H, H, Hal or A, R1 and R2 denote together alkylene having 3-5 C atoms, R3, R4 each, independently of each other, denote H, OA, OH or Hal, R3 and R4 together denote -0-CH2-CH2-, -0-CH2-0 - or -0-CH2-CH2-0, in Ih X denotes morpholinyl, 4-yl-piperidin-1-yl, 4-Y-piperazin-1-yl, 1-, 2-, 4- or 5-imidazolyl, 2-methyl-l-imidazol-1-yl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1 -, -4- or -5-yl, 1,2,4-triazol-1-, -3- or 5-yl, 3- or 4 - pyridazinyl or pyrazinyl, R1, R2 each, independently of each other, denote H, Hal or A, R1 and R2 together denote alkylene having 3-5 carbon atoms, each R37 R4 independently, denote H, OA, OH or Hal, R3 and R4 together denote -0-CH2-CH2-, -0-CH2-0- or -0-CH2-CH2-0, Y denotes H, A, OH, -CH20H or -CH2CH20H, and derivatives, solvates, and pharmaceutically useful stereoisomers thereof, including mixtures thereof in all ratios. Particular preference is given to the use of compounds selected from the group (a) 2- (1-imidazolyl) -6-methyl-4- (3,4-methylenedioxy-benzylamino) thieno [2,3-d] pyrimidine; (b) 2- (1-imidazolyl) -5,6-dimethyl-4- (3,4-methylene-dioxybenzylamino) thieno [2,3-d] pyrimidine; (c) 2- (1-imidazolyl) -4- (3,4-methylenedioxybenzylamine) -5,6,7,8-tetrahydro- [1] -benzylthieno [2,3-d] pyrimidine; (d) 2- (1-imidazolyl) -5-chloro-4- (3,4-methylenedioxy-benzylamino) thieno [2,3-d] pyrimidine; (e) 2- (1-imidazolyl) -6-chloro-4- (3,4-methylenedioxy-benzylamino) thieno [2,3-d] irimidine; (f) 2- (1,2,4-triazol-1-yl) -4- (3,4-methylenedioxybenzylamine) -5,6,7,8-tetrahydro- [1] -benzylthieno [2, 3 -d] pyrimidine; (g) 2- (pyrazol-1-yl) -4- (3,4-methylenedioxybenzylamine) -5,6,7,8-tetrahydro- [1] -benzylthieno [2,3-d] pyrimidine; (h) 2- (pyridin-3-yl) -4- (3,4-methylenedioxybenzylamine) -5,6,7,8-tetrahydro- [1] -benzylthieno [2,3-d] pyrimidine; (i) 2- (morpholin-4-yl) -4- (3,4-methylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno [2,3-d] pyrimidine; (j) 2- (morpholin-4-yl) -4- (3,4-methylenedioxybenzylamino) -5,6-dimethylthieno [2,3-d] pyrimidine. The pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient of each dosage unit. That unit may comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a compound according to the invention, depending on the condition treated, the method of administration and the age, weight and condition of the patient, or the pharmaceutical formulations can be administered in the form of dosage units comprising a predetermined amount of active ingredient per dosage unit. Formulations of the dosage unit are those comprising a dose or part of a daily dose as indicated above, or a corresponding fraction thereof of an active ingredient. In addition, pharmaceutical formulations of this type can be prepared using a process in which it is generally known in the pharmaceutical art. The pharmaceutical formulations can be adapted for administration via any suitable, desirable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous) methods. , intramuscular, intravenous or intradermal). These formulations can be prepared using all processes known in the pharmaceutical art, for example, by combining the active ingredient with excipients or adjuvants. Pharmaceutical formulations adapted for oral administration can be administered, as separate units, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or sparkling foods; or in liquid emulsions, oil in water or water-in-oil liquid emulsions. Thus, for example in the case of oral administration in the form of a tablet or capsule, the active ingredient component can be combined with a non-toxic, oral, pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like. The powders are prepared by grinding the compounds to a suitable fine size and mixing them with a similarly ground pharmaceutical excipient, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol. A flavoring, preservative, dispersant and dye can be present in the same way. The capsules are produced by preparing a powder mixture as described above and molding the molded parts or gelatin caps with it. Sliding and lubricating aggregates such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form can be added to the powder mixture before the filling operation. A disintegrant or solubilizer, such as, for example, agar-agar, calcium carbonate or sodium carbonate, can also be added to improve the availability of the drug after the capsule has been taken. In addition, if desired or necessary, suitable binders, lubricants and disintegrants, as well as dyes can be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from corn, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes and the like. Lubricants used in those dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrants include, but are not restricted to, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.

The tablets are formulated, for example, by preparing a powder mixture, granulating or dry pressing the mixture, adding lubricant and a disintegrant and pressing the whole mixture to give tablets. A powder mixture is prepared by mixing the comminuted compound in a suitable manner with a diluent or a base, as described above, and optionally with a binder such as, for example, carboxymethyl cellulose, an alginate, gelatin or polyvinylpyrrolidone, a water retardant dissolution, such as, for example, paraffin, an absorption accelerator, for example, a quaternary salt and / or an absorber, such as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acacia mucilage or solutions of cellulose or polymeric materials and pressing this through a screen. As an alternative to granulation, the powder mixture can be passed through a tabletting machine, giving lumps non-uniformly which are broken to form granules. The granules can be lubricated by the addition of stearic acid, a stearate salt, talc or mineral oil to prevent adhesion to the molds for molding tablets. The lubricated mixture is then pressed to give tablets. The compounds according to the invention can also be combined with a free-flowing inert excipient and then directly pressed into tablets without carrying out the granulation or dry pressing steps. A transparent or opaque protective layer consisting of a lacquer sealer layer, a layer of sugar or polymeric materials and a shiny layer of wax may be present. Dyes can be added to these coatings to differentiate between different dosage units. Oral liquids, such as, for example, solutions, syrups and elixirs, can be prepared in the form of dosage units, such that a given amount comprises a pre-specified amount of the compound. The syrups can be prepared by dissolving the compound in an aqueous solution with a suitable flavor, while the elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers may also be added, such as, for example, epoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavoring additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like. Dosage unit formulations for oral administration may, if desired, be encapsulated in microcapsules. The formulation can also be prepared in such a way that the release is prolonged or retarded, for example, by coating or including the particulate material in polymer, wax and the like. The compounds of formula I and the salts, solvates and physiologically functional derivatives thereof can also be administered in the form of liposomal delivery systems, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, for example, cholesterol, stearyl amine or phosphatidyl cholines. The compounds of formula I and the salts, solvates and physiologically functional derivatives thereof can also be released using monoclonal antibodies as individual supports to which the molecules of the compound are coupled. The compounds can also be coupled to soluble polymers as supports for targeted drugs. These polymers may include polyvinylpyrrolidone, pyran copolymers, polyhydroxy-propyl methacrylamidophenol, polyhydroxyethylaspartamidophenol or polyethylene oxide polylysine, substituted by palmitoyl radicals. The compounds can also be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of the drug, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates and amphiphilic block copolymers or hydrogel lattices. Pharmaceutical formulations adapted for transdermal administration can be administered as separate plaster for close, extended contact with the epidermis of the patient. Thus, for example, the active ingredient can be released from the plaster by iontophoresis, as described generally in Pharmaceutical Research, 3 (6), 318 (1986). The pharmaceutical compositions adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils. For the treatment of the eyes or other external tissue, for example, the mouth and the skin, the formulations are preferably applied as the ointment or topical cream. In the case of the ointment formulation, the active ingredient can be used with a water-miscible paraffin or cream base. Alternatively, the active ingredient may be formulated to give a cream with an oil-in-water cream base or a water-in-oil base. Pharmaceutical formulations adapted for topical application to the eyes include eye drops, in which the active ingredient is dissolved or suspended in a suitable vehicle, in particular an aqueous solvent.

Pharmaceutical formulations adapted for topical application in the mouth include troches, lozenges and mouthwashes. Pharmaceutical formulations adaptable for rectal administration can be administered in the form of suppositories or enemas. Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range of 20-500 microns, which is administered so that it is taken by aspiration, that is by rapid inhalation via the nasal passages of a container containing the powder held close to the nose. Formulations suitable for administration as a nasal spray or nasal drops with a liquid as a support substance can encompass solutions of the active ingredient in water or oil. Pharmaceutical formulations adapted for administration by inhalation encompass finely particulate powders or mists, which can be generated by various types of dispensers pressurized with aerosols, nebulizers or insufflators. Pharmaceutical formulations adapted for vaginal administration can be administered as weighings, buffers, creams, gels, pastes, foams or spray formulations. Pharmaceutical formulations adapted for parenteral administration include sterile aqueous and non-aqueous injectable solutions comprising antioxidants, buffers, bactoriostats and solutes, by means of which the formulation becomes isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise suspension media and thickeners. The formulations can be administered in single dose or multiple dose containers, for example ampoules and closed bottles, and stored in the dry state by freezing (lyophilization), so that only the addition of the sterile support liquid, for example water, is necessary. for injection purposes immediately before use. Injectable solutions and suspensions prepared according to the recipe can be prepared from sterile powders, granules and tablets. It goes without saying that, in addition to the constituents mentioned in particular above, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations that are suitable for oral administration may comprise flavorings.

A therapeutically effective amount of a compound of formula I depends on a number of factors, including, for example, the age and weight of the animal, the precise condition requiring treatment, and its severity, the nature of the formulation and the method of administration. , and finally it is determined by the treating doctor or veterinarian. However, an effective amount of a compound according to the invention for the treatment of neoplastic growth, for example colon or breast carcinoma, is generally in the range of 0.1 to 100 mg / kg of body weight of the receptor (mammal). per day and particularly typically in the range of 10 mg / kg body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as a single dose per day or usually in a series of separate doses (such as for example , two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt or solvate or a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound according to the invention per se. It can be assumed that similar doses are suitable for the treatment of other conditions mentioned above.

USE The compounds of the present are suitable as pharmaceutically active ingredients for mammals, especially for humans, in the treatment of diseases induced by tyrosine kinase. These diseases include the proliferation of tumor cells, pathological neovascularization (or angiogenesis) which promotes the growth of solid tumors, ocular neovascularization (diabetic retinopathy, age-induced macular degeneration and the like) and inflammation (psoriasis, rheumatoid arthritis and the like). The present invention encompasses the use of compounds of the formula I and / or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of cancer. Preferred carcinomas for treatment originate from the group of brain carcinoma, carcinoma of the urogenital tract, carcinoma of the lymphatic system, carcinoma of the stomach, carcinoma of the larynx and lung carcinoma. An additional group of preferred forms of cancer are monocytic leukemia, pulmonary adenocarcinoma, small cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma. Also covered is the use according to the invention according to claim 1 of the compounds and / or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of a disease in which the angiogenesis That disease in which angiogenesis is involved is an ocular disease, such as retinal vascularization, diabetic retinopathy, age-induced macular degeneration and the like. The use of compounds of formula I and / or physiologically acceptable salts or solvates thereof for the preparation of a medicament for the treatment or prevention of inflammatory diseases also falls within the scope of the present invention. Examples of those inflammatory diseases include rheumatoid arthritis, psoriasis, contact dermatitis, delayed hypersensitivity reaction and the like. Also encompassed are the uses of the compounds of formula I and / or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment or prevention of a tyrosine kinase-induced disease or a tyrosine kinase-induced condition in a mammal. , in which a therapeutically effective amount of a compound according to the invention is administered to a sick mammal in need of such treatment. The therapeutic amount varies according to the specific disease and can be determined by the person skilled in the art without undue effort. The present invention also encompasses the use of compounds of formula I and / or physiologically acceptable salts or solvates thereof for the preparation of a medicament for the treatment or prevention of retinal vascularization. Methods for the treatment or prevention of ocular diseases, such as diabetic retinopathy, and ocular degeneration induced by age, are likewise part of the invention. The use for the treatment or prevention of inflammatory diseases, such as rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reaction, as well as the treatment and prevention of bone pathology of the osteosarcoma group, osteoarthritis and rickets, likewise fall within of the scope of the present invention. The term "diseases or conditions induced by tyrosine kinase" refers to pathological conditions that depend on the activity of one or more tyrosine kinases. Tyrosine kinases participate directly or indirectly in the signal transduction pathways of a variety of cellular activities, including cell proliferation, adhesion, migration and differentiation. Diseases associated with tyrosine kinase activity include the proliferation of tumor cells, pathological neovascularization, which promotes the growth of solid tumors and ocular neovascularization (diabetic retinopathy)., macular degeneration induced by age and the like) and inflammation (psoriasis, rheumatoid arthritis and the like). The compounds of formula I can be administered to patients for the treatment of cancer. The compounds of the present invention inhibit tumor angiogenesis thereby affecting the growth of tumors (J. Rak et al .. Cancer Research, 55: 4575-4580, 1995). The inhibition properties of angiogenesis of the compounds of formula I hereof are also suitable for the treatment of certain forms of blindness related to retinal neovascularization. The compounds of formula I are also suitable for the treatment of certain bone pathologies, such as osteosarcoma, osteoarthritis, and rickets, also known as oncogenic osteomalacia (Hasegawa et al., Skeletal Radiol., 28, pp. 41-45, 1999; Gerber et al., Nature Medicine, Vol. 5 No. 6, pp.623-628, June 1999). Since VEGF directly promotes osteoclastic bone resorption through KDR / Flk-1 expressed in mature osteoclasts (FEBS Let. 473: 161-164 (2000); Endocrinology, 141: 1667 (2000)), the compounds of the present are also suitable for treatment and conditions related to bone resorption, such as osteoporosis and Page's disease.

The compounds can also be used for the reduction or prevention of tissue damage that occurs after cerebral ischemic events, stroke, reducing cerebral edema, tissue damage and reperfusion damage after ischemia (Drug News Perspect 11: 265-270 (1998 ), J. Clin Invest. 104 1613-1620 (1999)). The invention thus relates to the use of compounds of formula I and pharmaceutically useful derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of medicaments for the treatment of diseases in which The inhibition, regulation and / or modulation of kinase signal transduction plays a role. Preference is given here to the kinases selected from the tyrosine kinase group and Raf kinases. The tyrosine kinases are preferably TIE-2, VEGFR, PDGFR, FGFR and / or FLT / KDR. Preference is given to the use of compounds of formula I, and pharmaceutically useful derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios for the preparation of medicaments for the treatment of diseases which are influenced by the inhibition of tyrosine kinases by the compounds according to claim 1.

Particular preference is given to the use for the preparation of a medicament for the treatment of diseases that are influenced by the inhibition of TIE-2, VEGFR, PDGFR, FGFR and / or FLT / KDR by the compounds according to claim 1. It gives special preference to the use for the treatment of a disease where the disease is a solid tumor. The solid tumor is preferably selected from the group of tumors of the squamous epithelium, bladder, stomach, kidneys, head and neck, esophagus, cervix, thyroid, intestine, liver, brain, prostate, urogenital tract, lymphatic system, stomach, larynx and / or lung. The solid tumor is further preferably selected from the group of lung adenocarcinoma, small cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma. Preference is further given to the use for the treatment of a tumor of the blood or immune systems, preferably for the treatment of a tumor selected from the group of acute myelocytic leukemia, chronic myelocytic leukemia, acute lymphatic leukemia and / or chronic lymphatic leukemia. The invention also relates to the use of the compounds of formula I for the treatment of a disease in which angiogenesis is involved. The disease is preferably an eye disease. The invention also relates to the use for the treatment of retinal vascularization, diabetic retinopathy, age-induced macular degeneration and / or inflammatory diseases. The inflammatory disease is preferably selected from the group of rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions. The invention also relates to the use of the compounds according to the invention for the treatment of bone pathologies, where the bone pathology originates from the group of osteosarcoma, osteoarthritis and rickets. The compounds of formula I are suitable for the preparation of a medicament for the treatment of diseases that are caused, mediated and / or propagated by Raf kinases where the Raf kinase is selected from the group consisting of A-Raf, B-Raf and Raf -1. Preference is given to the use for the treatment of diseases, preferably of the group of hyperproliferative and non-hyperproliferative diseases. These are cancerous diseases or non-cancerous diseases. Non-cancerous diseases are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, hyperplasia, benign prostatic, immunological diseases, autoimmune diseases and diseases by immunity. Cancer diseases are selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, liver cancer, kidney cancer, colorectal cancer, breast cancer, head cancer, neck cancer, esophageal cancer, gynecological cancer, thyroid cancer, lymphoma, chronic leukemia and acute leukemia. The compounds of formula I can also be administered at the same time as other well-known therapeutic agents that are selected for their particular utility against the condition being treated. For example, in the case of bone conditions, combinations that would be favorable include those with antiresorptive bisphosphonates, such as alendronate and risedronate, integrin blockers (as defined below), as antagonists of av3, conjugated estrogens used in therapy of hormone replacement, such as Prempro®, Premarin®, and Endometrion®; selective estrogen receptor modulators (SERM), such as raloxifene, droloxifene, CP-336,156 (Pfizer) and lasofoxifene, cathepsin K inhibitors, and ATP proton pump inhibitors.

The compounds of the present invention are also suitable for combination with known anticancer agents. Such anti-cancer agents known include: modulators of estrogen receptor modulators androgen receptor, retinoid receptor modulators, cytotoxic agents, antiproliferative agents, prenyl protein transferase inhibitors, HMG-CoA reductase inhibitors, protease inhibitors of HIV, reverse transcriptase inhibitors and other angiogenesis inhibitors. The compounds of the present invention are particularly suitable for administration at the same time as radiotherapy. The synergistic effects of VEGF inhibition in combination with radiotherapy have been described in the art (See WO 00/61186). "Estrogen receptor modulators" refers to compounds that interfere with or inhibit the binding of estrogen to the receptor, regardless of the mechanism. Examples of estrogen receptor modulators include but are not limited to, tamoxifen, raloxifene, idoxifene, LY353381, LY 117081, toremifene, fulvestrant, 2, 2-dimethyl propyl 4- [7- (2,2-dimethyl-l- oxopropoxy-4-methyl-2- [4- [2- (1-piperidinyl) ethoxy] phenyl] -2H-l-benzopyran-3-yl] -phenyl, 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and SH646"Androgen receptor modulators" refers to compounds that interfere with or inhibit the binding of androgens to the receptor regardless of the mechanism Examples of androgen receptor modulators include finasteride and other 5D-reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole and abiraterone acetate. "retinoid receptor modulators" refers to compounds that interfere with or inhibit the binding of retinoids to the receptor, regardless of mechanism. examples of such modulators, retinoid receptor include bexarotene, tretinoin , 13-cis-retinoic acid, 9-ci acid s-retinoic acid, α-difluoromethylornithine, ILX23-7553, trans-N- (4'-hydroxyphenyl) retinamide and N-4-carboxyphenylretinamide. "Cytotoxic agents" refers to compounds which result in cell death primarily through direct action on cell function or inhibit or interfere with cell meiosis, including alkylating agents, tumor necrosis factors, intercalators, inhibitors of microtubulin and topoisomerase inhibitors. Examples of cytotoxic agents include, but are not limited to, tirapacimine, setain, cachectin, ifosfamide, tasonermin, lonidamine, carbopiatin, altretamine, prednimustine, dibromodulcitol, ranimustine, fotemustine, platin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosylate. , trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cispiatino, irofuiven, dexifosfamide, cis-amindicloro (2-methylpyridine) platinum, benzylguanine, glufosfamide, GPXIOO tetrachloride (trans, trans, trans) -bis -mu- (hexan-1, 6-diamine) mu- [diamin-platinum (II)] bis [diamino (chloro) platinum (II)], diaricidinyl-spermine, arsenic trioxide, 1- (11-dodecylamino-10) -hydroxyundecyl) -3,7-dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxantrone, pirarubicin, pinafide, vairubicin, amrubicin, antineopiastone, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarinomycin, annamicin, galarubi Cina, elinafide, MEN10755 and 4-demethoxy-3-deamino-3-acyridin-4-methyl-sulphonyldaunorubicin (see WO 00/50032). Examples of microtubulin inhibitors include paclitaxel, vindesine sulfate, 3 ', 4'-didehydro-4'-deoxy-8' -norvincaleucoblastina, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, 2,3,4,5, 6-pentafluoro-N- (3-fluoro-4-methoxyphenyl) enzymesulfon-amide, anhydrovinblastine, N, N-dimethyl-L-valyl-L-valyl-N-methyl -L-valyl-L-prolyl-L-prolin-t-butylamide, TDX258 and BMS188797. Some examples of topoisomerase inhibitors are the topotecan, hicaptamine, irinotecan, rubitecane, 6-ethoxypropionyl-3 ', 4'-O-exobenzylidenecartreusine, 9-methoxy-N, N-dimethyl-5-nitropyrazolo [, 4, 5-kil] cridin-2- (6H) - propanamine, l-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-lH, 12H-benzo [des] pyran [3 ', 4': b, 7] indolizine [ 1,2b] -quinolin-10,13 (9H, 15H) dione, lurtotecan, 7- [2- (N-isopropyl-amino) ethyl] - (20S) camptothecin, BNP1350, BNP11100, BN80915, BN80942, etoposide phosphate , teniposide, sobuzoxane, 2'-dimethylamino-2'-deoxy-toposide, GL331, N- [2- (dimethylamino) -ethyl] -9-hydroxy-5,6-dimethyl-6H-pyrido [4,3b] carbazole-1 -carboxamide, asulacrine, (5a, 5aB, 8aa, 9b) -9- [2- [N- [2- (dimethylamino) ethyl] -N-methylamino] ethyl] -5- [4-hydroxy-3, 5-dimethoxy-phenyl] -5,5a, 6,8,8a, 9-hexohydrofuro (3 ', 4': 6, 7) apto (2, 3-d) -1,3-dioxol-6-one, 2,3- (methylenedioxy) -5-methyl-7-hydroxy-8-methoxybenzo [c] phenanthridinium, 6,9-bis [(2-aminoethyl) amino] -benzo [g] isoquinoline-5,10-dione, 5- (3-Aminopropylamino) -7, 10-dihydroxy -2- (2-hydroxyethylaminomethyl) -6H-pyrazole [4,5,1-de] -acridin-6-one, N- [1- [2 (diethylamino) ethylamino] -7-methoxy-9-oxo-9H -thioxanten-4-ylmethyl] formamide, N- (2- (dimethylamino) ethyl) -acridine-4-carboxamide, 6- [[2- (dimethylamino) ethyl] amino] -3-hydroxy-7H-indene [2, lc] quinolin-7-one and dimesna. "Antiproliferative agents" include antisense DNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231 and INX3001 and antimetabolites such as enocythabin, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine ocphosphate, hydrate phosteabine sodium, raltitrexed, paltitrexid, emitefur, thiazofurine, decitabine, nolatrexed, pemetrexed, neizarabine, 2'-deoxy-2 '-methylidenecytidine, 2' -fluoromethylene-2 '-deoxycytidine, N- [5- (2, 3- dihydrobenzofuryl) sulfonyl] -N '- (3,4-dichlorophenyl) urea, N6- [4-deoxy-4- [N2 [2 (E), 4 (E) -tetradecadienoyl] glycylamino] -L-glycero-BL- mannoheptopyranosyl] adenine, aplidine, ecteinascidin, troxacitabine, 4- [2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino [5,4-b] -1,4-thiazin-6 -yl- (S) -ethyl] -2,5-thienoyl-L-glutamic acid, aminopterin, 5-fluorouracil, alanosine, l-acetyl-8- (carbamoyloxymethyl) -4-formyl-6-methoxy-14 -ester -oxa-l, 11-diazatetracyclo ( 7.4.1.0.0) -tetradeca-2,4,6-trien-9-ylacetic acid, swainsonin, lometrexol, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-lBD-arabinofuranosyl cytosine and 3- aminopyridine-2-carboxaldehyde thiosemicarbazone. "Antiproliferative agents" also include monoclonal antibodies to growth factors other than those listed under "angiogenesis inhibitors," such as trastuzumab, and tumor suppressor genes, such as p53, which can be released via mediated gene transfer. by recombinant viruses (see U.S. Patent No. 6,069,134, for example). The invention also relates to the use of compounds of formula I for the preparation of a medicament for the treatment of diseases, wherein the disease is characterized by disturbed angiogenesis. The diseases are preferably cancerous diseases. The perturbed angiogenesis preferably results from disturbed VEGFR-1, VEGFR-2 and / or VEGFR-3 activity. Therefore, particular preference is also given to the use of compounds according to the invention for the preparation of a medicament for the inhibition of VEGFR-2 activity. The invention also relates to compounds of formula I in which R1, R2 each, independently of each other denote H, A, OA, alkenyl, alkynyl, N02, CF3 or Hal, R1, R2 together also denote alkylene having 3-5 C atoms, R3, R4 each, independently denoting H, A, OA, OH, Hal, N02, NH2, NHA or NAA ', R3, and R4 together also denote -0-CH2-CH2-, -0-CH2-0-or -0-CH2-CH2-0-, A, A' each , independently of one another, denote alkyl having from 1 to 6 carbon atoms, wherein 1-5 H atoms can also be replaced by F and / or chlorine, X denotes morpholinyl, 4-Y-piperidin-1-yl or -Y-piperazin-1-yl, Y denotes H, A, OH, -CH2OH or -CH2CH2OH, Hal denotes F, Cl, Br or I and n denotes 0, 1, 2 or 3, and derivatives, solvates, salts and stereoisomers thereof pharmaceutically useful, including mixtures thereof in all ratios. The invention also relates to the use of optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and solvates of these compounds. Up and down, the radicals R1, R2, R3, R4, X, L and n have the meanings indicated for formula I, unless otherwise expressly stated. A and A ', independently of each other, preferably denote alkyl having 1-6 carbon atoms. In the above formulas, the alkyl is preferably unbranched and has 1, 2, 3, 4, 5 or 6 carbon atoms, preferably 1, 2, 3, 4 or 5 C atoms, and preferably denote methyl, ethyl or propyl, in addition, preferably isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, but also n-pentyl, neopentyl or isopentyl. Alkyl also denotes, for example, trifluoromethyl. The alkylene is preferably unbranched and preferably denotes propylene, butylene or pentylene. One of the radicals R1 and R2 preferably means H, while the other preferably denotes propyl or butyl, but particularly preferably ethyl or methyl. In addition, R1 and R2 also denote together preferably propylene, butylene or pentylene. Ri, R 2 particularly preferable each, independently of the other, denote H or A, or together denote alkylene having 3-5 C atoms. Hal preferably denotes F, Cl or Br, but also I, particularly preferably F or Cl. Alkenyl preferably means vinyl, 1- or 2-propenyl, 1-butenyl, isobutenyl, sec-butenyl, preference is further given to 1-pentenyl, isopentenyl or 1-hexenyl. Alkynyl preferably means ethynyl, propyne-1-yl, also butyne-1-butyne-2-yl, pentyne-1-, pentyne-2- or pentyne-3-yl. The radicals R3 and R4 can be identical or different and are preferably in the 3- and 4- position of the phenyl ring. They denote each, for example, independently of each other, H, alkyl, alkoxy, hydroxyl, nitro, amino, alkylamino, such as, for example, methylamino, dialkylamino, such as, for example, dimethylamino, F, Cl, Br, or I, or together denote ethyleneoxy, methylenedioxy, or ethylenedioxy. They preferably also mean each alkoxy, such as, for example, methoxy, ethoxy or propoxy. R3, R4 particularly preferably denote H, F, Cl, methoxy, hydroxyl or together denote 3, 4-methylenedioxy. The radical X preferably denotes 4-morpholinyl, 4-methylpiperazin-1-yl, 4 (2-hydroxyethyl) piperazin-1-yl or 4-hydroxypiperidin-1-yl. Through the invention, all the radicals that occur more than once can be identical or different, ie they are independent of each other. The compounds of formula I may have one or more chiral centers and may therefore occur in various stereoisomeric forms. Formula I covers all these forms. Accordingly, the invention relates, in particular, to the use of compounds of formula I, in which at least one of the radicals has one of the preferred meanings indicated above. Some groups of preferred compounds can be expressed by the following sub-formulas Iaa to Iae, which form the formula I and in which the radicals not designated in greater detail have the meanings indicated for the formula I, but in which Iaa R1, R2 each, independently of each other, denote H, A, OA, N02, CF3 or Hal, R3 and R4 together denote -0-CH2-CH2-, -0-CH2-0- or -0-CH2, -CH2, x denotes morpholinyl, and n denotes 1; in lab R1, R2 each, independently of each other, denote H, A, OA, NO2, CF3 or Hal, R3, R4 each, independently of each other, denote H, A, OA, Hal, N02, NH2, NHA or NAA ', X denotes morpholinyl, and n denotes 1; in lac R1 and R2 together denote alkylene having 3-5 carbon atoms, R3 and R4 together denote -0-CH2-CH2-, -0-CH2-0- or -0-CH2-CH2-0, X denotes morpholinyl , and n denotes 1; in which R1 and R2 together denote alkylene having 3-5 C atoms, R3, R4 each, independently of each other, denote H, A, OA, Hal, N02, NH2, NHA or NAA ', X denotes morpholinyl and n denotes 1; in Iae X denotes morpholinyl, 4-Y-piperidin-1-yl or 4-Y-piperazin-1-yl, R 1, R 2 each, independently of one another, denote H, Hal or A, R 1 and R 2 denote alkylene together has 3-5 C atoms, R3, R4 each, independently of each other, denote H, OA, OH or Hal,. R3 and R4 together denote -0-CH2-CH2-, -0-CH2-0- or -0-CH2-CH2-0, and pharmaceutically useful derivatives, solvates, and stereoisomers thereof, including mixtures thereof in all the relationships. Particular preference is given to the use of compounds selected from the group 2- (morpholin-4-yl) -4- (3,4-methylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno [2, 3 -d] pyrimidine; 2- (Morpholin-4-yl) -4- (3,4-methylenedioxybenzylamino) -5,6-dimethylthieno [2,3-d] pyrimidine. The compounds of formula I can preferably be obtained by reacting the compounds of formula II R, R, R, R and n have the same meanings indicated, and L denotes Cl, Br, OH, SCH3 or an esterified reactive group of OH, with the heterocyclic compounds containing N. L denotes an esterified reactive OH group, this is preferably alkylsulfonyloxy having 1-6 carbon atoms (preferably methylsulfonyloxy) or arylsulfonyloxy having 6-10 carbon atoms C (preferably phenyl- or p-tolylsulfonyloxy, in addition also 2-naphthalenesulfonyloxy). The precursors of the compounds of formula I can be prepared, for example, by cyclization and halogenation analogously to J. Med. Chem. 24,374 (1981). The subsequent reaction with arylalkylamine of the compounds of formula II. In detail, the reaction of the compounds of formula II with heterocyclic N-containing compounds is carried out in the presence or absence of an inert solvent at temperatures from about -20 to about 150 °, preferably between 20 and 100 °. The addition of an acid-binding agent, for example a hydroxide, carbonate or bicarbonate of alkali or alkaline earth metal, or of another salt of a weak acid of the alkaline or alkaline earth metals, preferably of potassium, sodium or calcium, or the addition of an organic base, such as triethylamine, dimethylamine, pyridine or quinoline, or an excess of the amine component may be favorable.

Suitable inert solvents are, for example, hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, such as trichlorethylene, 1,2-cyclohexene, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol, isopropanol, n-propanol or tet-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, such as ethylene glycol, monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme): ketones. like acetone or butanone; amides such as acetamide, dimethylacetamide or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as dimethyl sulfoxide (DMSO); nitro compounds, such as nitromethane or nitrobenzene; esters, such as ethyl acetate, or mixtures of solvents. A base of formula I can be converted into the associated acid addition salt using an acid, for example, by the reaction of equivalent amounts of the base and the acid in an inert solvent, such as ethanol, followed by evaporation. The acids suitable for this reaction are, in particular, those which give physiologically acceptable salts. Thus, it is possible to use inorganic acids, such as, for example, sulfuric acid, nitric acid, hydrohaluric acids, such as hydrochloric acid, or hydrobromic acid, phosphoric acids, such as orthophosphoric acid, sulfamic acid, as well as inorganic acids, in particular acids. aliphatic, alicyclic, araliphatic, aromatic or heterocyclic or mono- or polybasic carboxylic acids, sulphonic or sulfuric acids, for example formic acid, acetic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methano- or ethanesulfonic acid, ethanedisulfonic acid, 2-hydroxyethane sulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, Naphthalenmono-and disulphonic acids, aluryl sulfuric acid ico Salts with physiologically unacceptable acids, for example picrates, can be used for the isolation and / or purification of the compounds of formula I. On the other hand, the free acids of formula I can, if desired, be liberated from their salts using bases (for example sodium hydroxide or carbonate or potassium hydroxide or carbonate). In addition to the uses described above as kinase inhibitors, the compounds of formula I and the physiologically acceptable salts thereof can also be used as PDE inhibitors in the fight against diseases in which an increase in the level of GMPC (monophosphate cycloguanosine) results in the inhibition and prevention of inflammation, muscle relaxation. The compounds according to the invention can also be used in particular in the treatment of diseases of the cardiovascular system and for impotence therapy. The invention further relates to medicaments comprising at least one compound of formula I and / or pharmaceutically useful derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios and optionally excipients and / or adjuvants. These compositions can be used as medicines in humans or veterinary drugs. Suitable excipients are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical administration and do not react with novel compounds, for example water, vegetable oils, benzylic alcohols, alkylene glycols, polyethylene glycols, triacetate of glycerol, gelatin, carbohydrates, such as lactose or starch, magnesium stearate, talc, petrolatum. Suitable for oral use are, in particular, tablets, pills, dragees, capsules, powders, granules, syrups, juices or drops, suitable for rectal use are suppositories, suitable for parenteral use are solutions, preferably oil solutions or aqueous, in addition to suspensions, emulsions or implants, suitable for topical use are ointments, creams or powders, or also as nasal spray. The novel compounds can also be lyophilized and the resulting lyophilizates used, for example, for the preparation of injectable preparations. The compositions indicated can be sterilized and / or comprise adjuvants, such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for modifying the osmotic pressure, buffer substances, colorants, flavors and / or a plurality of active ingredients, eg Use one or more vitamins. ESSAYS The examples of formula I described in the examples were tested by the assays described below and found to have kinase inhibitory activity. Other assays are known from the literature and could easily be performed by one skilled in the art (see, for example, Dhanabal et al., Cancer Res. 59: 189-197.; Xin et al., J. "BioL Chem. 274: 9116-9121; Sheu et al., Anticancer Res. 18: 4435-4441; Ausprunk et al., Dev. Biol. 38: 237-248; Gimbrone et al. , J. Nati, Cancer Inst. 52: 413-427, Nicosia et al., In Vitro 18: 538-549.) VEGF receptor kinase assay The activity of the VEGF receptor kinase was measured by the incorporation of labeled phosphate. radioactively in polyglutaic acid / tyrosine substrate (pEY) 4: 1. The phosphorylated pEY product is trapped on a filter membrane and the incorporation of the radioactively labeled phosphate is quantified by the flashing count MATERIALS VEGF receptor kinase The domains in the intracellular tyrosine kinase Human KDR (Terman, B. 1. et al., Oncogene (1991) Vol. 6, pp. 1677-1683.) And Flt-1 (Shibuya, M. et al., Oncogene (1990) Vol. , pp. 519-524) were cloned as fusion proteins of the transferase glutathione (GST) gene. This was achieved by cloning the cytoplasmic domain of the KDR kinase as a fusion in the carboxyl terminal framework of the GST gene. The recombinant GST kinase domain fusion proteins were expressed in insect cells of Spodoptera frugiperda Sf21 (Invitrogen) using a baculovirus expression vector (pAcG2T, Pharmingen). 50 mM Tris lysis buffer pH 7.4, 0.5 M NaCl, 5 mM DTT, 1 mM EDTA, 0.5% Triton X-100, 10% glycerol, 10 mg / ml each of leupeptin, pepstatin and aprotinin and fluoride 1 mM phenylmethylsulfonyl (all from Sigma). 50 mM Tris wash buffer pH 7.4, 0.5 M NaCl, 5 mM DTT, 1 mM EDTA, 0.5% Triton X-100, 10% glycerol, 10 mg / ml each of leupeptin, pepstatin and aprotinin and fluoride 1 mM phenylmethyl sulfonyl dialysis buffer 50 mM Tris pH 7.4, 0.5 M NaCl, 5 mM DTT, 1 mM EDTA, 0.5% Triton X-100, 5% glycerol, 10 mg / ml each of leupeptin, pepstatin and aprotinin and 1 mM phenylmethylsulfonyl fluoride. 200 mM lOx Tris reaction buffer, pH 7.4, 1.0 M NaCl, 50 mM MnCl2, 10 mM DTT and 5 mg / ml bovine serum albumin [BSA] (Sigma). 50 mM Tris enzyme dilution buffer, pH 7.4, 0.1 M NaCl, 1 mM DTT, 10% glycerol, 100 mg / ml BSA. Substrate 10X 750 μg / ml poly (glutamic acid / tyrosine; 4: 1) (Sigma). Stopping Solution 30% trichloroacetic acid, 0.2 M sodium pyrophosphate (both from Fisher). Wash solution 15% trichloroacetic acid, 0.2 M sodium pyrophosphate Millipore #MAFC? OB filter plates, 96-well glass fiber plate GF / C. Method A - protein purification 1. Sf2l cells were infected with recombinant virus at a multiplicity of infection of 5 virus particles / cell and grown at 27 ° C for 48 hours. 2. All steps are carried out at 4 ° C. The infected cells were harvested by centrifugation at lOOOxg and lysed at 4 ° C for 30 minutes with 1/10 the volume of the lysis buffer followed by centrifugation at 10000xg for 1 hour. The supernatant was then passed over a glutathione Sepharose column (Pharmacia) equilibrated with lysis buffer and washed with 5 volumes of the same buffer followed by 5 volumes of wash buffer. The recombinant GST-KDR protein was eluted with 10 mM wash buffer / reduced glutathione (Sigma) and dialyzed against lysis buffer. Method B - VEGF receptor kinase assay 1. Add 5 μl of inhibitor or control to the assay in 50% DMSO. 2. Add 35 μl of reaction mixture containing 5 μl of reaction buffer lOx, 5 μl of 25 mM ATP / [33 P] ATP 10 μCi (Amersham) and 5 μl of substrate lOx. 3. Begin the reaction by adding 10 DI of KDR (25 mM) in enzyme dilution buffer. 4. Mix and incubate at room temperature for 15 minutes. 5. Stop the reaction by adding 50 DI of stop solution. 6. Incubate at 4 ° C for 15 minutes. 7. Transfer an aliquot of 90 ID to the filter plate. 8. Aspirate and wash three times with washing solution. 9. Add 30 μl of sparkling cocktail, seal the plate and count in a Wallace Microbeta flashing counter. Mitogenesis assay of endothelial cells of the human umbilical vein. The expression of VEGF receptors that mediate mitogenic responses to the growth factor greatly restricts vascular endothelial cells. Vascular endothelial cells of the human umbilical vein (HUVEC) in culture proliferate in response to treatment with VEGF and can be used as a test system to quantify the effects of KDR kinase inhibitors on VEGF stimulation. In the described assay, HUVEC monolayers were treated at rest with vehicle or test compound 2 hours before the addition of VEGF or basic fibroblast growth factor (bFGF). The mitogenic response to VEGF or BFGF was determined by measuring the incorporation of [3H] thymidine into cellular DNA. HUVEC Materials The frozen HUVEC as primary culture isolates were obtained from Clonetics Corp. The cells were obtained in the endothelial growth medium (EGM; Cionetics) and were used for mitogenic assays for 3-7 passes. Culture plates 96-well polystyrene tissue culture plates NUNCLON (NUNC # 167008). Test medium Modification of Dulbecco from Eagle's medium containing 1 g / ml of glucose (low DMEM in glucose, Mediatech) plus 10% (v / v) of fetal bovine serum (Clonetics). Test compounds The standard working solutions of the test compounds were serially diluted in 100% dimethylsulfoxide (DMSO) up to 400 times more than its desired final concentrations. The final dilutions at the 1 x concentration were made in assay medium immediately before addition to the cells. Growth factors lOx Solutions of human VEGF 165 (500 ng / ml, R & D Systems) and BFGF (10 ng / ml; R & D Systems) were prepared in assay medium. [3H] thymidine 10X [Methyl-3H] thymidine (20 Ci / mmol, Dupont-NEN) was diluted at 80 μCi / ml in low glucose DMEM medium.

Cell washing medium Hank's balanced salt solution (Mediatech) containing 1 mg / ml bovine serum albumin (Boehringer-Mannheim). Cell lysis solution NAOH 1N, 2% Na2C03 (w / v). Method 1 HUVEC monolayers maintained in EGM are harvested by trypsinization and cultured at a density of 4000 cells per 100 μl of assay medium per well in 96-well plates. Cell growth is counteracted for 24 hours at 37 ° C in a humidified atmosphere containing 5% C02. Method 2 The means for counteracting growth is replaced by 100 μl of vehicle containing test medium (0.25% DMSO [v / v]) or the desired final concentration of test compounds. All determinations were made in triplicate. The cells are then incubated at 37 ° C / 5% C02 for 2 hours to allow the test compounds to enter the cells. Method 3 After the 2 hour pretreatment period, the cells are stimulated with the addition of 10 μl / well of assay medium, VEGF lOx solution or BFGF lOx solution.

The cells are then incubated at 37 ° C / 5% C0. Method 4 After 24 hours in the presence of growth factors, [3 H] thymidine (10 μl / well) was added. Method 5 Three days after the addition of [3 H] thymidine, the medium was removed by aspiration, and the cells were washed twice with cell washing medium (400 μl / well followed by 200 μl / well). The washed, adherent cells are then solubilized with the addition of cell lysis solution (100 μl / well) and heating at 37 ° C for 30 minutes. The cell phones are transferred to glass bottles for 7 ml flashes containing 150 μl of water. The flash cocktail (5 ml / vial) is added, and the radioactivity associated with the cell is determined by flash spectroscopy in the liquid state. According to these tests, the compounds of formula I are inhibitors of VEGF and thus are suitable for the inhibition of angiogenesis, such as in the treatment of ocular diseases, for example diabetic retinopathy, and for the treatment of carcinomas, for example solid tumors. The compounds of the present invention inhibit VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values of 0.01-5.0 μM. These compounds also show selectivity to tyrosine kinases (for example FGFR1 and the Src family), for the relationship between Src kinases and VEGFR kinases, see Eliceiri et al., Molecular Cell, Vol. 4, pp.915-924, December 1999 ). The TIE-2 test can be carried out, for example, analogously to the methods indicated in WO 02144156. The test determines the inhibition activity of the substances to be tested in the phosphorylation of the poly (Glu, Tyr substrate ) by Tie-2 kinase in the presence of radioactive 33P-ATP. The phosphorylated substrate is attached to the surface of a microtitre plate, "flash plate" during the incubation time. After removal of the reaction mixture, the microtitre plate is washed a number of times and the radioactivity on its surface is subsequently measured. An inhibitory effect of the substances to be measured results in a lower radioactivity compared to an undisturbed enzymatic reaction. Up and down, all temperatures are indicated in ° C. In the following examples, "conventional work" means: if necessary, at a value between 2 and 10, depending on the constitution of the final product, the mixture is extracted with ethyl acetate or dichloromethane, the phases are separated, the organic phase it is dried over sodium sulphate and evaporated, and the product is purified by chromatography on silica gel and / or by crystallization.

Rf values on silica gel; eluent; ethyl acetate / methanol 9: 1. Mass spectrometry (MS): EI (electronic impact ionization) M + BAR (rapid atomic bombardment) (M + H) + ISES (electro-ionization ionization) (M + H) + Thienopyrimidine derivatives can be prepared analogously to the examples shown below. Example 1 3.02 g of 3,4-methylenedioxybenzylamine ("A") are added to a solution of 3.29 g of 2,4-dichloro-6-methylthieno [2,3-d] pyrimidine in 80 ml of dichloromethane, 1.52 are added. g of triethylamine, and the mixture is stirred at room temperature for 12 hours. The solvent is removed and subjected to conventional work, yielding 3.38 g of 2-chloro-6-methyl-4- (3,4-methylenedioxybenzylamino) thieno [2,3-d] pyridine, p. F. 162 ° C. Analogous reaction of "A" with 2, 4-dichloro-5-methylthieno- [2, 3-d] -pyrimidine gives 2-Chloro-5-methyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2-chloro-5,6,7,8-tetrahydro-4- ( 3, 4-methylenedioxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine, mp 222 °; with 2, 4-dichloro-5,6-cyclopenten- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-cyclopenten-4- (3,4-methylenedioxybenzylamino) -thieno - [2, 3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclohepten- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-cyclohepten-4- (3,4-methylenedioxybenzylamine) -thieno - [2, 3-d] -pyrimidine; with 2,4-dichloro-6-ethylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-ethyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine , pf 148 °; with 2,4,6-trichlorothieno- [2,3-d] -pyrimidine yields 2,6-dichloro-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4,5-trichloro-6-methylthieno- [2,3-d] -pyrimidine gives 2,5-dichloro-6-methyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2, 3- d] -pyrimidine; with 2, 4-dichloro-6-nitrothieno- [2,3-d] -pyrimidine gives 2-chloro-6-nitro-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-dimethylthieno- [2,3-d] -pyrimidine from 2-chloro-5,6-dimethyl-4- (3,4-methylenedioxybenzyl amino) -thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-trifluoromethyl-4- (3,4-methylenedioxy-benzylamino) -thieno- [2,3-d] -pyrimidine.

The analogous reaction of 3-chloro-4-methoxy-benzylamine with 2,4-dichloro-6-methylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-methyl-4- (3-chloro-4) -methoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5-methylthieno- [2, 3-d] -pyrimidine 2-Chloro-5-methyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6,7,8-tetra- [1] -benzothieno- [2,3-d] -pyrimidine gives 2-chloro-5,6,7,8-tetrahydro-4- ( 3-chloro-4-methoxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclopenten- [1] -benzothieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-cyclopenten-4- (3-chloro-4-methoxybenzylamino) -thien- [2, 3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclohepten- [1] -benzothieno- [2,3-.d] -pyrimidine gives 2-chloro-5,6-cyclohepten-4- (3-chloro-4-methoxybenzylamine ) -thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-6-ethylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-ethyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2, 3-d] -pyrimidine; with 2,4,6-trichlorothieno- [2,3-d] -pyrimidine yields 2,6-dichloro-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2, 4, 5-trichloro-6-methylthieno- [2,3-d] -pyrimidine gives 2,5-dichloro-6-methyl-4- (3-chloro-4-methoxy-benzylamino) -thieno- [ 2, 3-d] -pyrimidine; with 2,4-dichloro-6-nitrothieno- [2,3-d] -pyrimidine gives 2-chloro-6-nitro-4- (3-chloro-4-methoxybenzylamino) -thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-5,6-dimethylthieno ~ [2, 3-d] -pyrimidine gives 2-chloro-5,6-dimethyl-4- (3-chloro-4-methoxy-benzylamino) -thieno- [ 2, 3-d] -pyrimidine; with 2,4-dichloro-6-trifluoromethyl-thieno- [2,3-d] -pyrimidine gives 2-chloro-6-trifluoromethyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine. The analogous reaction of 3,4-dimethoxy-benzylamine with 2,4-dichloro-6-methylthieno- [2,3-d] -pyrimidine yields 2-chloro-6-methyl-4- (3,4-dimethoxybenzylamine) - thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-5-methylthieno- [2,3-d] -pyrimidine gives 2-chloro-5-methyl-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6,7,8-tetrahydro- [1] - [1] -benzothieno- [2, 3-d] -pyrimidine gives 2-chloro-5-, 6, 7, 8- tetrahydro-4- (3,4-dimethoxybenzyl aryl) - [1] -benzothieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclopenten- [1] -benzothieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-cyclopenten-4- (3,4-di-methoxybenzylamine) -thien- [2, 3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclohepten- [1] -benzothieno- [2,3-d] -pyrimidine from 2-chloro-5,6-cyclohepten-4- (3,4-di-methoxybenzylamine) -thien- [2, 3-d] -pyrimidine; with 2,4-dichloro-6-ethylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-ethyl-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4,6-trichlorothieno- [2,3-d] -pyrimidine yields 2,6-dichloro-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4,5-trichloro-6-methylthieno- [2,3-d] -pyrimidine yields 2,5-dichloro-6-methyl-4- (3,4-dimethoxybenzyl-amino) -thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-6-nitrothieno- [2,3-d] -pyrimidine from 2-chloro-6-nitro-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-dimethyl-4- (3,4-dimethoxybenzyl amino) -thieno- [2, 3 -d] -pyrimidine; with 2,4-dichloro-6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-trifluoromethyl-4- (3,4-dimethoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine. The analogous reaction of benzylamine with 2,4-dichloro-6-methylthieno- [2,3-d] -pyrimidine yields 2-chloro-6-methyl-4 ~ (3,4-dimethoxybenzylamino) -thieno- [2, 3 -d] -pyrimidine; with 2,4-dichloro-5-methylthieno- [2,3-d] -pyrimidine from 2-chloro-5-methyl-4-benzylaminothieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5, 6, 7, 8-tetrahydro- [1] - [1] -benzyl-thieno- [2,3-d] -pyrimidine gives 2-chloro-5, 6, 7, 8 -tetrahydro-4-benzylamino- [1] -benzothieno- [2, 3-d] -pyrimidine; with 2, 4-dichloro-5,6-cyclopenten- [1] -benzothieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-cyclopentene-4-benzylamino-thieno- [2, 3 d] -pyrimidine; with 2,4-dichloro-5,6-cyclohepten- [1] -benzothieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-cyclohepten-4-benzylamino-thieno- [2, 3- d] -pyrimidine; with 2,4-dichloro-6-ethylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-ethyl-4-benzylaminothieno- [2,3-d] -pyrimidine; with 2,4,6-trichlorothieno- [2,3-d] -pyrimidine yields 2,6-dichloro-4-benzylaminothieno- [2,3-d] -pyrimidine; with 2,4,5-trichloro-6-methylthieno- [2,3-d] -primimidine gives 2,5-dichloro-6-methyl-4-benzylaminothieno- [2,3-d] -pyrimidine; with 2,4-dichloro-6-nitrothieno- [2,3-d] -pyrimidine gives 2-chloro-6-nitro-4-benzylaminothieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-dimethyl-4-benzylaminothieno- [2,3-d] -pyrimidine; with 2,4-dichloro-6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-trifluoromethyl-4-benzylaminothieno- [2,3-d] -pyrimidine. The analogous reaction of 4-fluorobenzylamine with 2,4-dichloro-6-methylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-methyl-4- (4-fluorobenzylamino) -thieno- [2, 3 -d] -pyrimidine; with 2,4-dichloro-5-methylthieno- [2,3-d] -pyrimidine gives 2-chloro-5-methyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2-chloro-5,6,7,8-tetrahydro-4- ( 4-fluorobenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclopenten- [1] -benzothieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-cyclopenten-4- (4-fluorobenzylamino) -thieno- [ 2, 3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclohepten- [1] -benzothieno- [2,3-d] -pyrimidine yields 2-chloro-5,6-cyclohepten-4- (4-fluorobenzylamino) -thieno- [ 2, 3-d] -pyrimidine; with 2,4-dichloro-6-ethylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-ethyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4,6-trichlorothieno- [2,3-d] -pyrimidine yields 2,6-dichloro-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; with 2, 4, 5-trichloro-6-methylthieno- [2,3-d] -pyrimidine gives 2,5-dichloro-6-methyl-4- (4-fluorobenzylamino) -thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-6-nitrothieno- [2,3-d] -pyrimidine gives 2-chloro-6-nitro-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-dimethylthieno- [2,3-d] -pyrimidine from 2-chloro-5,6-dimethyl-4- (4-fluorobenzylamino) -thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-6-trifluoromethylthieno- [2,3-d] -pyrimidine yields 2-chloro-6-trifluoromethyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine. The analogous reaction of 3,4-dichlorobenzylamine with 2,4-dichloro-6-methylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-methyl-4- (3,4-dichlorobenzylamino) -thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-5-methylthieno- [2,3-d] -pyrimidine gives 2-chloro-5-methyl-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6,7,8-tetrahydro-4- ( 3, 4-dichlorobenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclopenten- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-cyclopenten-4- (3,4-dichlorobenzylamino) -thiene - [2, 3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclohepten- [1] -benzothieno- [2, 3-d] -pyrimidine gives 2-chloro-5,6-cyclohepten-4- (3,4-dichlorobenzylamino) -thiene - [2, 3-d] -pyrimidine; with 2,4-dichloro-6-ethyl-thieno- [2,3-d] -pyrimidine from 2-chloro-6-ethyl-4- (3,4-dichlorobenzylamino) -thieno- [2, 3-d] -pyrimidine; with 2,4,6-trichlorothieno- [2,3-d] -pyrimidine yields 2,6-dichloro-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4,5-trichloro-6-methylthieno- [2,3-d] -pyrimidine gives 2,5-dichloro-6-methyl-4- (3,4-dichlorobenzylamino) -thieno- [2, 3- d] -pyrimidine; with 2,4-dichloro-6-nitrothieno- [2, 3-d] -pyrimidine gives 2-chloro-6-nitro-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-dimethyl-4- (3,4-dichlorobenzyl-amino) -thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-6-trifluoromethylthieno- [2,3-d] -pyrimidine from 2-chloro-6-trifluoromethyl-4- (3,4-dichlorobenzyl-amino) -thieno- [2,3-d] -pyrimidine. The analogous reaction of 3-nitrobenzylamine with 2,4-dichloro-6-methylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-methyl-4- (3-nitrobenzylamino) -thieno- [2, 3 -d] -pyrimidine; with 2,4-dichloro-5-methylthieno- [2, 3-d] -pyrimidine 2-Chloro-5-methyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6,7,8-tetrahydro-4- ( 3-nitro-benzylamino) - [1] -benzothieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclopenten- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-cyclopenten-4- (3-nitro-benzylamino) -thieno - [2, 3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclohepten- [1] -benzylthieno- [2,3-d] -pyrimidine from 2-chloro-5,6-cyclohepten-4- (3-nitro-benzylamino) -thieno - [2, 3-d] -pyrimidine; with 2,4-dichloro-6-ethylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-ethyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4,6-trichlorothieno- [2,3-d] -pyrimidine yields 2,6-dichloro-4- (3-nitrobenzylamin) -thieno- [2,3-d] -pyrimidine; with 2,4,5-trichloro-6-methylthieno- [2,3-d] -pyrimidine gives 2,5-dichloro-6-methyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-6-nitrothieno- [2,3-d] -pyrimidine gives 2-chloro-6-nitro-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-dimethylthieno- [2,3-d] -pyrimidine from 2-chloro-5,6-dimethyl-4- (3-nitrobenzylamino) -thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-6-trifluoromethylthieno- [2,3-d] -pyrimidine from 2-chloro-6-trifluoromethyl-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine . The analogous reaction of 3,4-methylenedioxyphenethylamine with 2,4-dichloro-6-methylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-methyl-4- (3,4-methylene-phenethylamino) -thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-5-methylthieno- [2,3-d] -pyrimidine from 2-chloro-5-methyl-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6,7,8-tetrahydro-4- ( 3, 4-methylenedioxyphenethylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclopenten- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-cyclopenten-4- (3,4-methylenedioxyphenethylamino) -thieno - [2, 3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclohepten- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-cyclohepten-4- (3,4-methylenedioxyphenethylamino) -thieno - [2, 3-d] -pyrimidine; with 2,4-dichloro-6-ethylthieno- [2,3-d] -pyrimidine gives 2-chloro-6-ethyl-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; with 2,4,6-trichlorothieno- [2,3-d] -pyrimidine yields 2,6-dichloro-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; with 2,4,5-trichloro-6-methylthieno- [2,3-d] -pyrimidine gives 2,5-dichloro-6-methyl-4- (3,4-methylenedioxyphenethylamino) -thieno- [2, 3- d] -pyrimidine; with 2, 4-dichloro-6-nitrothieno- [2,3-d] -pyrimidine gives 2-chloro-6-nitro-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-dimethyl-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-6-trifluoromethylthieno- [2,3-d] -pyrimidine from 2-chloro-6-trifluoromethyl-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrimidine. The analogous reaction of 3,4-ethylenedioxybenzylamine with 2,4-dichloro-6-methylthieno- [2,3-d] -pyrimidine yields 2-chloro-6-methyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5-methylthieno- [2,3-d] -pyrimidine from 2-chloro-5-methyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6,7,8-tetrahydro-4- ( 3, 4-ethylenedioxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclopenten- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-cyclopenten-4- (3,4-ethylene-dioxybenzylamine) -thien- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-cyclohepten- [1] -benzylthieno- [2,3-d] -pyrimidine from 2-chloro-5,6-cyclohepten-4- (3,4-ethylene-dioxybenzylamine) -thien- [2,3-d] -pyrimidine; with 2,4-dichloro-6-ethylthieno- [2,3-d] -pyrimidine from 2-chloro-6-ethyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4,6-trichlorothieno- [2,3-d] -pyrimidine from 2,6-dichloro-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2, 4, 5-trichloro-6-methylthieno- [2,3-d] -pyridine gives 2,5-dichloro-6-methyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3- d] -pyrimidine; with 2,4-dichloro-6-nitrothieno- [2, 3-d] -pyrimidine gives 2-chloro-6-nitro-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; with 2,4-dichloro-5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2-chloro-5,6-dimethyl-4- (3,4-ethylenedioxybenzyl-amino) -thieno- [2, 3-d] -pyrimidine; with 2,4-dichloro-6-trifluoromethylthieno- [2,3-d] -pyrimidine from 2-chloro-6-trifluoromethyl-4- (3,4-ethylenedioxy-benzylamino) -thieno- [2,3-d] -pyrimidine. Example 2 1.67 g of 2-chloro-6-methyl-4- (3,4-methylenedioxy-benzylamino) -thieno- [2,3-d] -pyrimidine, 1.02 g of imidazole and 2 g of phenol are heated to 150 ° for 5 hours. After cooling, the residue is dissolved in dichloromethane and subjected to conventional work, yielding 1.0 g of 2- (imidazol-1-yl) -6-methyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3 -d] -pyrimidine, mp 248-250 °. The analogous reaction of imidazole with the 2-chloro-thieno- [2,3-d] -pyrimidine substituted with 4-arylalkylamino derivatives obtained under Example 1 yields the following compounds 2- (imidazol-1-yl) -5- methyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine, mp 238 °; 2- (imidazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-methylenedioxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine, m.p. 218 °; 2- (imidazol-1-yl) -5,6-cyclopenten-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine, m.p. 260 °; 2- (imidazol-1-yl) -5,6-cyclohepten-4- (3,4-methylene-dioxybenzyl-amino) -thieno- [2,3-d] -pyrimidine, m.p. 210 °; 2- (imidazol-1-yl) -6-ethyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine, methanesulfonate, m.p. 201 °; 2- (imidazol-1-yl) -6-chloro-4- (3,4-methylenedioxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-chloro-6-methyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2-imidazol-1-yl) -6-nitro-4- (3,4-methylenedioxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-dimethyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyridine, m.p. 245 °; 2- (imidazol-1-yl) -6-trifluoromethyl-4- (3,4-methylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-methyl-4- (3-chloro-4-methoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-methyl-4- (3-chloro-4-methoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6,7,8-tetrahydro-4- (3-chloro-4-methoxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclopenten-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclohepten-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-ethyl-4- (3-chloro-4-methoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-chloro-4- (3-chloro-4-methoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-chloro-6-methyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-nitro-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-dimethyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-trifluoromethyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-methyl-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-methyl-4- (3,4-dimethoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5, 6, 7, 8-tetrahydro-4- (3,4-di-methoxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclopenten-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclohepten-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-ethyl-4- (3,4-dimethoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-chloro-4- (3,4-dimethoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-chloro-6-methyl-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-nitro-4- (3,4-dimethoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-dimethyl-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-trifluoromethyl-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-methyl-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-methyl-4-benzylaminothieno- [2,3-d] -pyrimidine, m.p. 207 °; 2- (imidazol-1-yl) -5-methyl-4-benzylaminothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6,7,8-tetrahydro-4-benzylamino- [1] -benzothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclopentene-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclohepten-4-benzylamino-thieno- [2,3-d] -pyrimidine, m.p. 197 °; 2- (imidazo-1-yl) -6-ethyl-4-benzylaminothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-chloro-4-benzylaminothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-chloro-6-methyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-nitro-4-benzylaminothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-dimethyl-4-benzylaminothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-trifluoromethyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-methyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-methyl-4- (4-fluorobenzylamino) • thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6,7,8-tetrahydro-4- (4-fluoro-benzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclopenten-4- (4-fluoro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazo-1-yl) -5,6-cyclohepten-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-ethyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine, m.p. 199 °; 2- (imidazo-1-yl) -6-chloro-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-chloro-6-methyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-nitro-4- (4-fluorobenzylamino) thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-dimethyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazo-1-yl) -6-trifluoromethyl-4- (4-fluoro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-methyl-4- (3,4-dichlorobenzylamino) -thiene-. [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-methyl-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-di-chlorobenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclopenten-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclohepten-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-ethyl-4- (3,4-dichlorobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-chloro-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-chloro-6-methyl-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-nitro-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-dimethyl-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-trifluoromethyl-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-methyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-methyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6,7,8-tetrahydro-4- (3-nitro-benzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclopenten-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclohepten-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-ethyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-chloro-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-chloro-methyl-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-nitro-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-dimethyl-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-trifluoromethyl-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-methyl-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-methyl-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-methylenedioxyphenethylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclopenten-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclohepten-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-ethyl-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-chloro-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-chloro-6-methyl-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-nitro-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-dimethyl-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-trifluoromethyl-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-methyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-methyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5, 6, 7, 8-tetrahydro-4- (3,4-ethylene-dioxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclopenten-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-cyclohepten-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-ethyl-4- (3, -ethylenedioxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-chloro-4- (3,4-ethylenedioxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5-chloro-6-methyl-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-nitro-4- (3,4-ethylenedioxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -5,6-dimethyl-4- (3,4-ethylenedioxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (imidazol-1-yl) -6-trifluoromethyl-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine. The analogous pyrazole reaction with 2-chlorothieno- [2,3-d] -pyrimidine substituted with 4-arylalkylamino derivatives obtained under Example 1 yields the following compounds 2- (pyrazol-1-yl) -5-methyl-4 - (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-methylene-dioxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine, mp, 210 °; 2- (pyrazol-1-yl) -5,6-cyclopenten-4- (3,4-methylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclohepten-4- (3,4-methylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-ethyl-4- (3,4-methylenedioxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-chloro-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-chloro-6-methyl-4- (3,4-methylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-nitro-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-dimethyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-trifluoromethyl-4- (3,4-methylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-methyl-4- (3-chloro-4-methoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-methyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6,7,8-tetrahydro-4- (3-chloro-4-methoxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclopenten-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclohepten-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-ethyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-chloro-4- (3-chloro-4-methoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine, 2- (pyrazol-1-yl) -5-chloro-6-methyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-nitro-4- (3-chloro-4-methoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-dimethyl-4- (3-chloro-4-methoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-trifluoromethyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-methyl-4- (3,4-dimethoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-methyl-4- (3,4-dimethoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-di-methoxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclopenten-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclohepten-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-ethyl-4- (3,4-dimethoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-chloro-4- (3,4-dimethoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-chloro-6-methyl-4- (3, 4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-nitro-4- (3,4-dimethoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-dimethyl-4- (3,4-dimethoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-trifluoromethyl-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-methyl-4- (3,4-dimethoxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-methyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6,7,8-tetrahydro-4-benzylamino- [1] -benzothieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclopentene-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclohepten-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-ethyl-4-benzylamino-thieno- [2,3-d] pyrimidine; 2- (pyrazol-1-yl) -6-chloro-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-chloro-6-methyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-nitro-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-dimethyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-trifluoromethyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-methyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-methyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6,7,8-tetrahydro-4- (4-fluoro-benzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclopentene-4- (4-fluorobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclohepten-4- (4-fluoroboenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-ethyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine, 2- (pyrazol-1-yl) -6-chloro-4 - (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-chloro-6-methyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-nitro-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-dimethyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-trifluoromethyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-methyl-4- (3,4-dichlorobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-methyl-4- (3,4-dichlorobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-dichloro-benzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclopentene-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclohepten-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-ethyl-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-chloro-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-chloro-6-methyl-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-nitro-4- (3,4-dichlorobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-dimethyl-4- (3,4-dichlorobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-trifluoromethyl-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-methyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-methyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6,7,8-tetrahydro-4- (3-nitro-benzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclopenten-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclohepten-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-ethyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-chloro-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-chloro-6-methyl-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-nitro-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-dimethyl-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-trifluoromethyl-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-methyl-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-methyl-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-methylene-dioxyphenethylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclopenten-4- (3,4-methylene-dioxyphenethyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclohepten-4- (3,4-methylene-dioxyphenethyl-amino) -thieno- [2,3-d] -pyrimidine; '2- (pyrazol-1-yl) -6-ethyl-4- (3,4-methylenedioxyphenethyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-chloro-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-chloro-6-methyl-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-nitro-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-dimethyl-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-trifluoromethyl-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-methyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-methyl-4- (3,4-ethylenedioxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-ethylene-dioxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclopenten-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-cyclohepten-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-ethyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-chloro-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5-chloro-6-methyl-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-nitro-4- (3,4-ethylenedioxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -5,6-dimethyl-4- (3,4-ethylenedioxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (pyrazol-1-yl) -6-trifluoromethyl-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine. The analogous reaction of 1,2,4-triazole with 2-chloro-thieno- [2,3-d] -pyrimidine derivatives substituted with 4-arylalkylamino obtained under Example 1 yields the following compounds 2- (1,2, 4-triazol-1-yl) -5-methyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-methylenedioxybenzyl amino) - [1] -benzothieno- [2, 3-d ] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclopenten-4- (3,4-methylenedioxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclohepten-4- (3,4-methylenedioxybenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-ethyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-chloro-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-chloro-6-methyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-nitro-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-dimethyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-trifluoromethyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-methyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-methyl-4- (3-chloro-4-methoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6,7,8-tetrahydro-4- (3-chloro-4-methoxybenzyl-amino) - [1] -benzothieno- [2,3 -d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclopenten-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclohepten-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-ethyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-chloro-4- (3-chloro-4-methoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-chloro-6-methyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-nitro-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-dimethyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-trifluoromethyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-methyl-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-methyl-4- (3,4-dimethoxybenzylamino) -thieno- [2-, 3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-dimethoxybenzylamino) - [1] -benzylthieno- [2,3-d] - pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclopenten-4- (3,4-di-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclohepten-4- (3,4-di-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-ethyl-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-chloro-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-chloro-6-methyl-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1, 2, 4-triazol-1-yl) -6-nitro-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-dimethyl-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-trifluoromethyl-4- (3,4-di-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-methyl-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-methyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6,7,8-tetrahydro-4-benzyl-amino- [1] -benzo-thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclopentene-4-benzyl-amino-thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclohepten-4-benzyl-amino-thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-ethyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (1, 2, 4-triazol-1-yl) -6-chloro-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-chloro-6-methyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-nitro-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (1, 2, 4-triazol-1-yl) -5,6-dimethyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-trifluoromethyl-4-benzyl-amino-thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-methyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-methyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6,7,8-tetrahydro-4- (4-fluorobenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclopentene-4- (4-fluoro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclohepten-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-ethyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2, -triazol-1-yl) -6-chloro-4- (4-fluorobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-chloro-6-methyl-4- (4-fluoro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-nitro-4- (4-fluorobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-dimethyl-4- (4-fluoro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-trifluoromethyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-methyl-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-methyl-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-dichlorobenzylamino) - [1] -benzothieno- [2,3-d] - pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclopenten-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclohepten-4- (3,4-di-chlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2, -triazol-1-yl) -6-ethyl-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-chloro-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-chloro-6-methyl-4- (3,4-di-chlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-nitro-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-dimethyl-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-trifluoromethyl-4- (3,4-di-chlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1, 2, 4-triazol-1-yl) -6-methyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-methyl-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6,7,8-tetrahydro-4- (3-nitrobenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclopenten-4- (3-nitro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclohepten-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-ethyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-chloro-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-chloro-6-methyl-4- (3-nitro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1, 2, 4-triazol-1-yl) -6-nitro-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-dimethyl-4- (3-nitro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-trifluoromethyl-4- (3-nitro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-methyl-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-methyl-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-methylenedioxyphenethylamino) - [1] -benzothieno- [2,3-d] - pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclopenten-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclohepten-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrine; 2- (1,2,4-triazol-1-yl) -6-ethyl-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrine; 2- (1, 2, 4-triazol-1-yl) -6-chloro-4- (3,4-methylenedioxy-phenethylamino) -thieno- [2,3-d] -pyrine; 2- (1,2,4-triazol-1-yl) -5-chloro-6-methyl-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrine; 2- (1,2,4-triazol-1-yl) -6-nitro-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrine; 2- (1,2,4-triazol-1-yl) -5,6-dimethyl-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrine; 2- (1,2,4-triazol-1-yl) -6-trifluoromethyl-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrine; 2- (1,2,4-triazol-1-yl) -6-methyl-4- (3, 4-ethylenedioxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-methyl-4- (3, 4-ethylenedioxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-ethylenedioxybenzylamino) - [1] -benzothieno- [2, 3-d] - pyrimidine; 2- (1, 2,4-triazol-1-yl) -5,6-cyclopenten-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclohepten-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-ethyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-chloro-4- (3, 4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5-chloro-6-methyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-nitro-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-dimethyl-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -6-trifluoromethyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine. The analogous reaction of 2-methylimidazole with substituted 2-chloro-thieno- [2,3-d] -pyrimidine 4-arylalkylamino derivatives obtained under Example 1 yields the following compounds 2- (2-methylimidazol-1-yl) - 5-methyl-4- (3, -methylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-Methylimidazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-methylenedioxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine, amorphous; 2- (2-methylimidazol-1-yl) -5,6-cyclopenten-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclohepten-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-ethyl-4- (3,4-methylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-chloro-4- (3,4-methylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-chloro-6-methyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-nitro-4- (3,4-methylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-dimethyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-trifluoromethyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-methyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-methyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6,7,8-tetrahydro-4- (3-chloro-4-methoxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclopentene-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (1,2,4-triazol-1-yl) -5,6-cyclohepten-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-ethyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-chloro-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-Methylimidazol-1-yl) -5-chloro-6-methyl-4- (3-chloro-4-methoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-Methyl-1-yl) -6-nitro-4- (3-chloro-4-methoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-dimethyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-trifluoromethyl-4- (3-chloro-4-methoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-methyl-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-methyl-4- (3,4-dimethoxy-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-dimethoxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclopenten-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-Methylimidazol-1-yl) -5,6-cyclohepten-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-ethyl-4- (3, 4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-chloro-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-chloro-6-methyl-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-nitro-4- (3, -dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-dimethyl-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-trifluoromethyl-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-methyl-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-methyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6,7,8-tetrahydro-4-benzylamino- [1] -benzylthieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclopentene-4-benzyl-amino-thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclohepten-4-benzyl-amino-thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-ethyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-chloro-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-chloro-6-methyl-4-benzyl-amino-thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-nitro-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-dimethyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-trifluoromethyl-4-benzylamino-thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-methyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-methyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6,7,8-tetrahydro-4- (4-fluorobenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclopentene-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclohepten-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-ethyl-4- (4-fluorobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-chloro-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-chloro-6-methyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-nitro-4- (4-fluoro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-dimethyl-4- (4-fluoro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-trifluoromethyl-4- (4-fluorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-methyl-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-methyl-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-dichlorobenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclopentene-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclohepten-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-ethyl-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-chloro-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-chloro-6-methyl-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-nitro-4- (3,4-dichloro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-dimethyl-4- (3,4-di-chlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-Methylimidazol-1-yl) -6-trifluoromethyl-4- (3,4-dichlorobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-methyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-methyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-Mithimidazol-1-yl) -5,6,7,8-tetrahydro-4- (3-nitrobenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclopentene-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclohepten-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-ethyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-chloro-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-chloro-6-methyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-nitro-4- (3-nitrobenzyl-amino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-dimethyl-4- (3-nitro-benzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-trifluoromethyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-methyl-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-methyl-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-methylenedioxyphenethylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclopenten-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclohepten-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-ethyl-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-chloro-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-Methylimidazol-1-yl) -5-chloro-6-methyl-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-nitro-4- (3,4-methylene-dioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-dimethyl-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-trifluoromethyl-4- (3,4-methylenedioxyphenethylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-Methylimidazol-1-yl) -6-methyl-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-methyl-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-Methylimidazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-ethylenedioxybenzylamino) - [1] -benzothieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclopenten-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-cyclohepten-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-ethyl-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-chloro-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5-chloro-6-methyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -6-nitro-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-methylimidazol-1-yl) -5,6-dimethyl-4- (3,4-ethylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine; 2- (2-Methylimidazol-1-yl) -6-trifluoromethyl-4- (3,4-ethylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine. Example 3 5 g 2-amino-5-methyl-3-ethoxycarbonyl thiophene was dissolved in 40 ml of dioxane with 2.7 g 3-cyanopyridine in 40 ml. Subsequently, gaseous HCl was passed through the solution for 5 hours. Conventional work gives 6 g of 3,4-hihydro-4-oxo-2- (pyridin-3-yl) -6-methyl-thieno- [2,3-d] -pyrimidine. The replacement of the keto group with Cl with formation of the aromatic pyridine anillom is carried out under standard conditions. A mixture of 18 ml of P0C13 with 6 g 3, 4-dihydro-4-oxo-2- (pyridin-3-yl) -6-methyl-thieno- [2,3-d] -pyrimidine with the addition of 1.8 ml of N, N-dimethylaniline is boiled for 4 hours. Conventional work gives 5 g 4-chloro-2- (pyridin-3-yl) -6-methyl-thieno- [2,3-d] -pyrimidine. The analogous reaction of 3-cyanopyridine and subsequent reaction with POCl3 of 2-amino-4-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-3-yl) -5-methyl-thieno- [2, 3 d] -pyrimidine; of 2-amino-4, 5,6,7-tetrahydro-3-ethoxycarbonyl-benzothiophene gives 4-chloro-2- (pyridin-3-yl) -5,6,7,8-tetrahydro- [1] -benzothien - [2, 3-d] -pyrimidine, mp 143 °; of 2-amino-4,5-cyclopentene-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-3-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine; of 2-amino-4, 5-cyclohepten-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-3-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine; of 2-amino-5-ethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-3-yl) -6-ethylthieno- [2,3-d] -pyrimidine; of 2-amino-5-chloro-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-3-yl) -6-chlorothieno- [2,3-d] -pyrimidine; of 2-amino-4-chloro-5-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-3-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; of 2-amino-5-nitro-3-ethoxycarbonyl-thiophene gives 4-chloro-2- (pyridin-3-yl) -6-nitrothieno- [2,3-d] -pyrimidine; of 2-amino-4,5-dimethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-3-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine; of 2-amino-5-trifluoromethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-3-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine. The analogous reaction of 5-cyanoisoxazole and the subsequent reaction with POCl3 of 2-amino-5-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (isoxazol-5-yl) -6-methylthieno- [2,3-d] ] -pyrimidine; of 2-amino-4-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (isoxazol-5-yl) -5-methylthieno- [2,3-d] -pyrimidine; of 2-amino-4, 5,6,7-tetrahydro-3-ethoxycarbonyl-benzothiophene gives 4-chloro-2- (isoxazol-5-yl) -5,6,7,8-tetrahydro- [1] -benzothieno - [2,3-d] -pyrimidine; of 2-amino-4,5-cyclopentene-3-ethoxycarbonylthiophene gives 4-chloro-2- (isoxazol-5-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine; of 2-amino-4,5-cyclohepten-3-ethoxycarbonylthiophene gives 4-chloro-2- (isoxazol-5-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine; of 2-amino-5-ethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (isoxazol-5-yl) -6-ethylthieno- [2,3-d] -pyrimidine; of 2-amino-5-chloro-3-ethoxycarbonylthiophene gives 4-chloro-2- (isoxazol-5-yl) -6-chlorothieno- [2,3-d] -pyrimidine; of 2-amino-4-chloro-5-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (isoxazol-5-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; of 2-amino-5-nitro-3-ethoxycarbonylthiophene gives 4-chloro-2- (isoxazol-5-yl) -6-nitrothieno- [2,3-d] -pyrimidine; of 2-amino-4,5-dimethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (isoxazol-5-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine; of 2-amino-5-trifluoromethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (isoxazol-5-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine. The analogous reaction of 2-cyanopyrazine and the subsequent reaction with POCl3 of 2-amino-5-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyrazin-2-yl) -6-methylthieno- [2, 3-d ] -pyrimidine; of 2-amino-4-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyrazin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine; of 2-amino-4, 5,6,7-tetrahydro-3-ethoxycarbonyl-benzothiophene gives 4-chloro-2- (pyrazin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno - [2,3-d] -pyrimidine; of 2-amino-4, 5-cyclopenten-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyrazin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine; of 2-amino-4, 5-cyclohepten-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyrazin-2-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine; of 2-amino-5-ethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyrazin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine; of 2-amino-5-chloro-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyrazin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine; of 2-amino-4-chloro-5-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyrazin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; of 2-amino-5-nitro-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyrazin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine; of 2-amino-4,5-dimethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyrazin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine; of 2-amino-5-trifluoromethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyrazin-2-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine. The analogous reaction of 2-cyanopyridine and the subsequent reaction with P0C13 of 2-amino-5-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-2-yl) -6-methylthieno- [2,3-d] ] -pyrimidine; of 2-amino-4-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine; of 2-amino-4, 5,6,7-tetrahydro-3-ethoxycarbonyl-benzothiophene gives 4-chloro-2- (pyridin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno - [2,3-d] -pyrimidine; of 2-amino-4,5-cyclopentene-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine; of 2-amino-4,5-cyclohepten-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-2-yl) -5,6-cycloheptyrtiene- [2,3-d] -pyrimidine; of 2-amino-5-ethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine; of 2-amino-5-chloro-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine; of 2-amino-4-chloro-5-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; of 2-amino-5-nitro-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine; of 2-amino-4,5-dimethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine; of 2-amino-5-trifluoromethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-2-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine. The analogous reaction of 4-cyanopyridine and the subsequent reaction with POCl3 of 2-amino-5-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-4-yl) -6-methylthieno- [2,3-d] ] -pyrimidine; of 2-amino-4-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-4-yl) -5-methylthieno- [2,3-d] -pyrimidine; of 2-amino-4, 5, 6, 7-tetrahydro-3-ethoxycarbonyl-benzothiophene gives 4-chloro-2- (pyridin-4-yl) -5,6,7,8-tetrahydro- [1] -benzothien - [2, 3-d] -pyrimidine; of 2-amino-4,5-cyclopentene-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-4-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine; of 2-amino-4,5-cyclohepten-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-4-yl) -5,6-cycloheptyrtiene- [2,3-d] -pyrimidine; of 2-amino-5-ethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-4-yl) -6-ethylthieno- [2,3-d] -pyrimidine; of 2-amino-5-chloro-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-4-yl) -6-chlorothieno- [2,3-d] -pyrimidine; of 2-amino-4-chloro-5-methyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-4-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; of 2-amino-5-nitro-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-4-yl) -6-nitrothieno- [2,3-d] -pyrimidine; of 2-amino-4,5-dimethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-4-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine; of 2-amino-5-trifluoromethyl-3-ethoxycarbonylthiophene gives 4-chloro-2- (pyridin-4-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine. Example 4 Analogously to Example 1, the reaction of 3,4-methylenedioxy-benzylamine with 4-chloro-2- (pyridin-3-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxybenzylamino) -6-methyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxybenzylamine) -5 -methyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine, mp 215 °; with 4-chloro-2- (pyridin-3-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxybenzylamine) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cyclohepten-thieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3, 4- methylenedioxy-benzylamino) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-ethyl-thieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxybenzylamine) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxybenzylamine) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3, 4- methylenedioxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-nitrothieno- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxybenzylamine) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxybenzylamine) -5, 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylene- dioxybenzylamino) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxybenzylamine) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxybenzyl-amino) -5-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6,7,8-tetrahydro-fl] -benzothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) - 4- (3,4-methylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzo-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxy) benzylamino) -5,6-cyclo-pententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxy) benzylamino) -5,6-cycloheptyrtiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxybenzylamine) -6 -ethylthieno- [2,3-d] -pyrimidine; 4-Chloro-2- (isoxazol-5-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxybenzyl-amino) - 6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3, 4- methylenedioxybenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxybenzylamine) -6 -nitro-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxy) benzylamino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxybenzylamine) -6 -trifluoromethyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxybenzylamine) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxybenzyl-amino) -5-methyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyracin-2-yl) -4- (3,4-methylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxybenzylamine) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cyclohepten- ene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxy) benzylamino) -5,6-cycloheptentiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxybenzyl-amino) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxybenzylamino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-chloro-6-methylthieno- [2, 3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3, 4- methylenedioxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxybenzylamine) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxybenzyl) amino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-trifluoror-ethyl-thienyl- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxybenzylamine) -6 -trifluoromethyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxybenzylamine) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxybenzylamine) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxy) benzylamino) -5,6-cyclopenten-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxybenzylamine) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxybenzylamine) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxybenzyl-amino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3, 4- methylenedioxybenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxybenzylamine) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxybenzylamine) -5,6-Dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pririmidin a da 2- (pyridin-2-yl) -4- (3,4-methylenedioxybenzylamine) - 6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxybenzyl-amino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxybenzylamine) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxybenzylamino) -5,6, * 7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine, mp 185 °; with 4-chloro-2- (pyridin-4-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxy) benzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxybenzylamine) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxybenzylamine) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxybenzylamine) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3, 4- methylenedioxybenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxybenzyl-amino) -6-nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxybenzylamine) -5, 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxybenzylamine) -6 -trifluoromethylthieno- [2,3-d] -pyrimidine. The analogous reaction of 3-chloro-4-methoxy-benzylamine with 4-chloro-2- (pyridin-3-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl ) -4- (3-chloro-4-methoxybenzylamino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-chloro-4-methoxybenzyl- amino) -5-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-chloro-4-methoxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzo-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-chloro-4-) methoxy-benzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with • 4-Chloro-2- (pyridin-3-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-chloro-4) -methoxy-benzylamino) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-chloro-4-methoxybenzyl) amino) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-chloro-4-methoxybenzyl- amino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-chloro- 4-methoxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-nitrothieno- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-chloro-4-methoxybenzyl- amino) -6-nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-chloro-4-) methoxybenzylamino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-chloro-4-methoxy) benzylamino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-chloro-4-methoxybenzyl) amino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-chloro-4-methoxybenzylamino) -5-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-Chloro-4-methoxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-chloro-4-) methoxybenzylamino) -5,6-cyclo-pententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-chloro-4-) methoxybenzylamino) -5,6-cycloheptyrtiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-chloro-4-methoxybenzyl) amino) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-chloro-4-methoxybenzylamino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-chloro- 4-methoxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- '(isoxazol-5-yl) -4- (3-chloro-4-methoxybenzyl) -amino) -6-nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-chloro-4-) methoxy-benzylamino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-chloro-4-methoxybenzylamine) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-chloro-4-methoxybenzylamino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-chloro-4-methoxybenzyl- amino) -5-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyracin-2-yl) -4- (3-chloro-4-methoxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-chloro-4-) methoxybenzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine * gives 2- (pyrazin-2-yl) -4- (3-chloro-4) -methoxy-benzylamino) -5,6-cyclohepteniene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-chloro-4-methoxybenzyl- amino) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-chloro-4-methoxybenzyl- amino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-chloro- 4-methoxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-chloro-4-methoxybenzyl) amino) -6-nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-chloro-4-) methoxy-benzyl-amino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-chloro-4-methoxybenzylamino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-chloro-4-methoxybenzyl- amino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-chloro-4-methoxybenzyl- amino) -5-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-chloro-4-methoxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-chloro-4-) methoxy-benzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-chloro-4-) methoxy-benzylamino) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-chloro-4-methoxybenzyl- amino) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-chloro-4-methoxybenzylamino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-chloro-6-methylthieno- [2 3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-chloro-4) -methoxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-nitrothieno- [2, 3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-chloro-4-methoxybenzylamino) -6-nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-chloro-4-) methoxy-benzyl-amino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-chloro-4-methoxy) benzylamino) -6-trifluoromethylthieno- [2,3-d] -pyrimidi? a; with 4-chloro-2- (pyridin-4-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-chloro-4-methoxybenzylamino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-chloro-4-methoxybenzyl- amino) -5-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-chloro-4-methoxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-chloro-4-) methoxybenzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-chloro-4-) methoxy-benzylamino) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-chloro-4-methoxybenzyl- amino) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-chloro-4-methoxybenzyl- amino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-chloro- 4-methoxy-benzylamino) -5-chloro-6-methyltiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-chloro-4-methoxybenzyl- amino) -6-nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-chloro-4-) methoxy-benzyl-amino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-chloro-4-methoxybenzylamino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; The analogous reaction of 3,4-dimethoxybenzylamine with 4-chloro-2- (pyridin-3-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dimethoxybenzylamino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dimethoxybenzylamine) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dimethoxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dimethoxy- benzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cycloheptyrtiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dimethoxy- benzylamino) -5,6-cycloheptentiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dimethoxybenzylamine) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-chlorothieno- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dimethoxybenzylamine) -6 -chlorotiene- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3, 4- dimethoxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-nitrothieno- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dimethoxybenzylamine) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-dimethylthieno- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dimethoxybenzylamine) -5,6-Dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dimethoxy-benzylamino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dimethoxybenzylamine) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (lsoxazol-5-yl) -4- (3,4-dimethoxybenzylamine) -5 -methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dimethoxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dimethoxy-) benzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cycloheptyrtiene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dimethoxybenzylamine) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dimethoxybenzylamine) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-chlorothieno- [2, 3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dimethoxybenzylamine) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (lsoxazol-5-yl) -4- (3, 4- dimethoxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dimethoxybenzylamine) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dimethoxy-) benzylamino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-di- methoxybenzylamino) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dimethoxybenzylamine) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dimethoxybenzylamine) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyracin-2-yl) -4- (3,4-dimethoxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dimethoxybenzylamine) -5,6-cyclopententiene- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dimethoxy-) benzylamino) -5,6-cycloheptentiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dimethoxybenzylamine) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dimethoxybenzylamine) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3, 4- dimethoxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dimethoxybenzylamine) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dimethoxybenzyl) amino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dimethoxy-benzylamino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3, -dimethoxybenzylamine) -6- methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dimethoxybenzylamine) -5 -methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dimethoxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dimethoxy- benzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dimethoxy-) benzylamino) -5,6-cycloheptentiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dimethoxybenzylamino) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dimethoxybenzylamino) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3, 4- dimethoxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dimethoxybenzylamine) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dimethoxybenzyl) amino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-trifluoromethylthieno- [2, 3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dimethoxy-benzylamino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dimethoxybenzylamine) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dimethoxybenzylamine) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dimethoxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dimethoxy- benzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dimethoxy- benzylamino) -5,6-cycloheptentiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dimethoxybenzylamine) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dimethoxybenzylamine) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3, 4- dimethoxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrirnidine; with 4-chloro-2- (pyridin-4-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dimethoxybenzylamine) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dimethoxybenzyl) amino) -5,6-dimethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3, -dimethoxybenzylamine) -6- trifluoromethylthieno- [2,3-d] -pyrimidine. The analogous reaction of 4-fluoro-benzylamine with 4-chloro-2- (pyridin-3-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-benzylamino- 6-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-benzylamino-5-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-benzylamino-5, 6,7, 8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine, mp 189 °; with 4-chloro-2- (pyridin-3-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-benzylamino-5,6-cyclopententiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-benzylamino-5,6-cyclohepteniene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-benzylamino-6-ethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-benzylamino-6-chlorothieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-benzylamino-5-chloro -6-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-nitrothieno- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-benzylamino-6-nitrothien- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-benzylamino-5,6-dimethyl -thien- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-benzylamino-6-tri-fluoromethyl-thienen- [ 2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-benzylamino-6-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-benzylamino-5-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (lsoxazol-5-yl) -4-benzylamino-5, 6,7, 8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-benzylamino-5,6-cyclopententiene - [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-benzylamino-5,6-cyclohepteniene - [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-benzylamino-6-ethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-benzylamino-6-chlorothieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) r4-benzylamino-5-chloro- 6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-benzylamino-6-nitrothien- [2, 3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-benzylamino-5,6-dimethylthien - [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-benzylamino-6-trifluoromethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-benzylamino-6-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-benzylamino-5-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyracin-2-yl) -4- benzylamino-5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-benzylamino-5,6-cyclopententiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-benzylamino-5,6-cyclohepteniene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-benzylamino-6-ethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-benzylamino-6-chlorothieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-benzylamino-5-chloro - 6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-benzylamino-6-nitrothien- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-benzylamino-5,6-dimethyl -thien- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-benzylamino-6-trifluoromethyl-thieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-benzylamino-6-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-benzylamino-5-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-benzylamino-5, 6,7, 8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-benzylamino-5,6-cyclopententiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cyclohepten-thieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-benzylamino-5,6 -cyclohepteniene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-benzylamino-6-ethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-benzylamino-6-chlorothieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-benzylamino-5-chloro - 6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-benzylamino-6-nitrothien- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-benzylamino-5,6-dimethyl -thien- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-benzylamino-6-tri-fluoromethyl-thienen- [ 2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-benzylamino-6-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-benzylamino-5-methylthieno- [2, 3 -d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-benzylamino-5, 6,7, 8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-benzylamino-5,6-cyclopententiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-benzylamino-5,6-cyclohepteniene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-benzylamino-6-ethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-benzylamino-6-chlorothieno- [2, 3 -d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-benzylamino-5-chloro -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-benzylamino-6-nitrothien- [2, 3 -d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-benzylamino-5,6-dimethyl -thien- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-benzylamino-6-tri-fluoromethyl-thienen- [ 2, 3-d] -pyrimidine. The analogous reaction of 4-fluorobenzylamine with 4-chloro-2- (pyridin-3-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (4 -fluorobenzylamino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (4-fluorobenzylamino) -5-methylthien - [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (4-fluorobenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (4-fluorobenzylamino) -5 , 6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (4-fluorobenzylamino) -5 , 6-cyclohepteniene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (4-fluorobenzylamino) -6-ethyl-tiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-chlorothieno- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (4-fluorobenzylamino) -6-chlorothien - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (4-fluorobenzyl- amino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (4-fluorobenzylamino) -6-nitrothien - [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (4-fluorobenzylamino) -5 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-trifluoromethyl-thieno- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (4-fluorobenzylamino) -6-trifluoromethyl-triene - [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (4-fluorobenzylamino) -6-methylthiene - [2, 3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (4-fluorobenzylamino) -5-methylthiene - [2, 3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (4-fluorobenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (4-fluorobenzylamino) -5 , 6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (4-fluorobenzylamino) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (4-fluorobenzylamino) -6-ethyl-tiene - [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-chlorothieno- [2, 3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (4-fluorobenzylamino) -6-chlorothieno - [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (4-fluorobenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (4-fluorobenzylamino) -6-nitrothien - [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (4-fluorobenzylamino) -5, 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives .2- (isoxazol-5-yl) -4- (4-fluoro-benzylamino) - 6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (4-fluorobenzylamino) -6-methylthiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (4-fluorobenzylamino) -5-methylthiene - [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyracin-2-yl) -4- (4-fluorobenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (4-fluorobenzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (4-fluorobenzylamino) -5 , 6-cyclohepteniene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (4-fluorobenzylamino) -6-ethyl-tiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (4-fluorobenzylamino) -6-chlorothien - [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (4-fluorobenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (4-fluorobenzylamino) -6-nitrothien - [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (4-fluorobenzylamino) -5 , 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (4-fluorobenzylamino) -6-trifluoromethyl-triene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine yields 2- (pyridin-2-yl) -4- (4-fluorobenzylamino) -6-methylthiene - [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (4-fluorobenzylamino) -5-methylthiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (4-fluorobenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (4-fluorobenzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5, -cyclohepteniene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (4-fluorobenzylamino) -5, 6-cyclohepteniene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (4-fluorobenzylamino) -6-ethyl-tiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (4-fluorobenzylamino) -6-chlorothiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (4-fluorobenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (4-fluorobenzylamino) -6-nitrothien - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-dimethylthieno- [2, 3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (4-fluorobenzylamino) -5 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-trifluoromethyl-thieno- [2, 3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (4-fluorobenzylamino) -6-trifluoromethyl-triene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (4-fluorobenzylamino) -6-methylthiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (4-fluorobenzylamino) -5-methylthiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (4-fluorobenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (4-fluorobenzylamino) -5 , 6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (4-fluorobenzylamino) -5 , 6-cyclohepteniene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (4-fluorobenzylamino) -6-ethyl-tiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (4-fluorobenzylamino) -6-chlorothieno - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (4-fluorobenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (4-fluorobenzylamino) -6-nitrothien - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (4-fluorobenzylamino) -5 , 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (4-fluorobenzylamino) -6 -trifluoromethylthieno- [2,3-d] -pyrimidine. The analogous reaction of 3,4-dichlorobenzylamine with 4-chloro-2- (pyridin-3-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dichlorobenzylamino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dichlorobenzylamino) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dichlorobenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dichlorobenzyl- amino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dichlorobenzylamino) -5,6-cyclohepteniene- [2,3-d] -pyrimidine, - with 4-chloro-2- (pyridin-3-yl) -6-ethylthieno- [2, 3-d] -pyrimidine gives 2- ( pyridin-3-yl) -4- (3,4-dichlorobenzylamino) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dichlorobenzylamino) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3, 4- dichlorobenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dichlorobenzylamino) -6 -nitrothieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dichlorobenzyl- amino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-dichlorobenzyl-amino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dichlorobenzylamino) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dichlorobenzylamino) -5 -methythieno- [2,3-d] -pyrimidine; with '4-chloro-2- (isoxazol-5-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) ) -4- (3,4-dichlorobenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dichloro- benzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cycloheptyrtiene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dichloro- benzylamino) -5,6-cycloheptentiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dichlorobenzylamino) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dichlorobenzylamino) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3, 4- dichloro-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dichlorobenzylamino) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dichloro- enylamino) - 5,6-dimethylthieno ~ [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-trifluoromethyl-ieno- [2, 3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-dichloro- enylamino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dichlorobenzylamino) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dichlorobenzylamino) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyracin-2-yl) -4- (3,4-dichlorobenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dichlorobenzyl- mino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dichlorobenzyl- mino) -5,6-cyclohepteniene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dichlorobenzylamino) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dichlorobenzylamino) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-chloro-6-methylthieno- [2, 3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3, 4- dichloroencyl-mino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dichlorobenzylamino) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dichlorobenzyl- mino) -5,6-dimethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-dichlorobenzyl-mino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dichlorobenzylamino) -6 -methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dichlorobenzylamino) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dichlorobenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dichlorobenzyl- mino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dichlorobenzyl- mino) -5,6-cyclohepteniene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dichlorobenzylamino) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dichlorobenzylamino) -6 -chlorotiene- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3, 4- dichlorobenzyl-mino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-nitrothieno- [2, 3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dichlorobenzylamino) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dichlorobenzyl- amino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-dichlorobenzylamino) -6 -trifluoromethyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dichlorobenzylamino) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dichlorobenzylamino) -5 -methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dichlorobenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dichlorobenzyl- amino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dichlorobenzylamino) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dichlorobenzylamino) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dichlorobenzylamino) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3, 4- dichlorobenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dichlorobenzylamino) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dichlorobenzyl- amino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-dichlorobenzylamino) -6 -trifluoromethylthieno- [2,3-d] -pyrimidine. The analogous reaction of 3-nitrobenzylamine with 4-chloro-2- (pyridin-3-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3 -nitrobenzylamino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-methylthieno- [2,3-d] -pyrimidin-2- (pyridin-3-yl) -4- (3-nitrobenzylamino) -5-methyl -thien- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-nitrobenzylamino) -5,6,7,8-tetrahydro- [1] -benzothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-nitrobenzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-nitrobenzylamino) -5 , 6-cyclohepteniene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-nitrobenzylamino) -6-ethyl-tiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-chlorothieno- [2,3-d] -primimidine gives 2- (pyridin-3-yl) -4- (3-nitrobenzylamino) -6-chlorothiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-nitrobenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-nitroatiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-nitrobenzylamino) -6-nitrothiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-nitrobenzylamino) -5 , 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3-nitrobenzylamino) -6-trifluoromethyl-triene - [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-nitrobenzylamino) -6-methyl tiene - [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-nitrobenzylamino) -5-methylthiene - [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-nitrobenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-nitrobenzylamino) -5 , 6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2 -, (isoxazol-5-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine- 2- (isoxazol-5-yl) -4- (3-nitrobenzylamino) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-nitrobenzylamino) -6-ethyl -thien- [2, 3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-nitrobenzylamino) -6-chloro -thien- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-nitrobenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-nitrothieno [2, 3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-nitrobenzylamino) -6-nitro- thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-hydobenzyl-amino) - 5,6-Dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-trifluoromethylthieno- [2, 3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3-nitro-benzylamino) -6 -trifluoromethyl-triene- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-nitrobenzylamino) -6-methylthien - [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-methyl-thieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-nitrobenzylamino) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyracin-2-yl) -4- (3-nitrobenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-nitrobenzylamino) -5 , 6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-nitrobenzylamino) -5 , 6-cyclohepteniene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-nitrobenzylamino) -6-ethyl -thien- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-chloro-thieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-nitrobenzylamino) -6 -chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-nitrobenzylam- mino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-nitrobenzylamino) -6-nitrothien - [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-nitrobenzylamino) -5 , 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3-nitrobenzylamino) -6-trifluoromethyl-triene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-nitrobenzylamino) -6-methylthiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-nitrobenzylamino) -5-methylthien - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-nitrobenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-nitrobenzylamino) -5 , 6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-nitrobenzylamine) -5,6-cycloheptynethio- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-nitrobenzylamino) -6-ethyl -thien- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-nitrobenzylamino) -6-chlorothien - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-nitrobenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-nitrobenzylamino) -6-nitrothien - [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-nitrobenzylamino) -5 , 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3-nitrobenzylamino) -6-trifluoromethyl thienyl - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-nitrobenzylamino) -6-methyl - thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-nitrobenzylamino) -5-methylthiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-nitrobenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-nitrobenzylamino) -5 , 6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-nitrobenzylamino) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-nitrobenzylamino) -6-ethyl -thien- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-nitrobenzylamino) -6-chlorothiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-nitrobenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-nitrothieno- [2, 3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-nitrobenzylamino) -6-nitrothiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-nitrobenzylamino) -5 , 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3-nitrobenzylamino) -6-trifluoromethyl thienyl - [2,3-d] -pyrimidine. The analogous reaction of 3,4-methylenedioxyphenethylamine with 4-chloro-2- (pyridin-3-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxyphenethylamino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxyphenethylamino) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (Pir5idin-3-yl) -4- (3,4-methylenedioxyphenethylamino) -5,6,7,8-tetrahydro- [1] -benzyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxyphenethylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxy) phenethylamino) -5,6-cycloheptyrene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxy-phenethylamino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3, 4- methylenedioxyphenethylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxyphenethylamino) -5, 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -trifluoromethyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxyphenethyl-amino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxyphenethylamino) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxyphenethylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxy) phenethylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxy) phenethylamino) -5,6-cycloheptyrene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3, 4- methylenedioxyphenethylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxyphenethyl-amino) -6-nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylenedioxyphenethylamino) -5, 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-methylene- dioxyphenethylamino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyracin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -5,6-cyclo-pententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxyphenethyl-amino) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3, 4- methylenedioxyphenethylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -5, 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-methylenedioxy-phenethylamino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with '4-chloro-2- (pyridin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxyphenethylamino) - 6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cycloheptyrtiene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxy) phenethylamino) -5,6-cycloheptyrene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3, 4- methylenedioxy-phenethylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -5, 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -trifluoromethyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxyphenethyl-amino) -5-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxyphenethylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxy) phenethylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxy) phenethylamino) -5,6-cycloheptyrene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -chlorotiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3, 4- methylenedioxyphenethylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-methylenedioxyphenethylamino) -6 -nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrimin-4-yl) -5,6-dimethyl-thieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3, 4- methylenedioxy-phenethylamino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3, -methylenedioxyphenethylamino) -6- trifluoromethylthieno- [2,3-d] -pyrimidine. The analogous reaction of 3,4-ethylenedioxybenzylamine with 4-chloro-2- (pyridin-3-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-ethylenedioxybenzylamino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-ethylenedioxybenzyl-amino) -5-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-ethylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-ethylenedioxybenzylamine) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-ethylenedioxy) benzylamino) -5,6-cycloheptentiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-ethylenedioxybenzylamino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3, 4- ethylenedioxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-ethylenedioxybenzyl) amino) -5,6-dimethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4- (3,4-ethylenedioxy-benzylamino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-ethylenedioxybenzylamino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-ethylenedioxybenzyl-amino) -5-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-ethylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-ethylenedioxy) benzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-ethylenedioxy) benzylamino) -5,6-cycloheptentiene- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (lsoxazol-5-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3, 4- ethylenedioxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-ethylenedioxy) benzylamino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4- (3,4-ethylene-dioxybenzylamine) -6-rifluorometyltieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-ethylenedioxybenzylamine) -5 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyracin-2-yl) -4- (3,4-ethylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-ethylenedioxy) benzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-ethylenedioxybenzylamine) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-ethylenedioxybenzylamine) -6 -ethyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-chloro-6-methylthieno- [2, 3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3, 4- ethylenedioxybenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-ethylenedioxybenzyl) amino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4- (3,4-ethylenedioxybenzylamine) -6 -trifluoromethyl-thieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-ethylenedioxybenzylamine) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-ethylenedioxybenzyl-amino) -5-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-ethylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-ethylenedioxy) benzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-ethylenedioxybenzylamine) -5,6-cycloheptynethio- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3, 4- ethylenedioxybenzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-ethylenedioxybenzylamine) -5, 6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4- (3,4-ethylenedioxy-benzylamino) -6-trifluoromethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-ethylenedioxybenzylamine) -6 -methythieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-ethylenedioxybenzylamino) -5-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-ethylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-ethylenedioxy) benzylamino) -5,6-cyclopententiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cycloheptyrtiene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-ethylenedioxy) benzylamino) -5,6-cycloheptentiene- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-ethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-chlorothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3, 4- ethylenedioxy-benzylamino) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-ethylenedioxybenzyl-amino) -6-nitrothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-ethylenedioxybenzyl) amino) -5,6-dimethylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-trifluoromethyl-thieno- [2, 3-d] -pyrimidine gives 2- (pyridin-4-yl) -4- (3,4-ethylenedioxybenzylamine) -6 -trifluoromethylthieno- [2,3-d] -pyrimidine. The analogous reaction of phenethylamine with 4-chloro-2- (pyridin-3-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-phenethylamino-6- methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-phenethylamino-5-methylthieno- [2, 3 -d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-phenethylamino-5, 6,7, 8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-phenethylamino-5,6-cyclopententiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-cycloheptyrtiene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-phenethylamino-5,6-cyclohepten -thien- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-phenethylamino-6-ethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-phenethylamino-6-chlorothieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-phenethylamino-5-chloro -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-nitrothieno- [2, 3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-phenethylamino-6-nitrotiene- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-phenethylamino-5,6-dimethyl -thien- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-3-yl) -6-trifluoromethyl-triene- [2,3-d] -pyrimidine gives 2- (pyridin-3-yl) -4-phenethylamino-6-tri-fluoromethyl-triene- [ 2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-phenethylamino-6-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-phenethylamino-5-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-phenethylamino-5, 6,7, 8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-phenethylamino-5,6-cyclopenten -thien- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-phenethylamino-5,6-cyclohepteniene - [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-phenethylamino-6-ethylthieno- [2, 3 -d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-phenethylamino-6-chlorothieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-phenethylamino-5-chloro -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-phenethylamino-6-nitrothien- [2, 3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-phenethylamino-5,6-dimethylthien - [2,3-d] -pyrimidine; with 4-chloro-2- (isoxazol-5-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (isoxazol-5-yl) -4-phenethylamino-6-trifluoromethyl-thieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-phenethylamino-6-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-phenethylamino-5-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyracin-2-yl) -4-phenethylamino-5, 6,7, 8-tetrahydro- [1] -benzylthienothieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-phenethylamino-5,6-cyclopententiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-phenethylamino-5,6-cyclohepteniene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-phenethylamino-6-ethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-phenethylamino-6-chlorothieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-phenethylamino-5-chloro -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-phenethylamino-6-nitrothien- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-phenethylamino-5,6-dimethyl -thien- [2,3-d] -pyrimidine; with 4-chloro-2- (pyrazin-2-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine gives 2- (pyrazin-2-yl) -4-phenethylamino-6-trifluoromethyl-thieno- [2,3- d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-phenethylamino-6-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-phenethylamino-5-methylthieno- [2, 3 -d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-phenethylamino-5, 6, 7, 8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-phenethylamino-5,6-cyclopententiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-cycloheptyrene- [2, 3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-phenethylamino-5,6-cycloheptyrtiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-phenethylamino-6-ethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-phenethylamino-6-chlorothieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-phenethylamino-5-chloro -6-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-phenethylamino-6-nitrothien- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-phenethylamino-5,6-dimethyl -thien- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-2-yl) -6-trifluoromethyl-thieno- [2,3-d] -pyrimidine gives 2- (pyridin-2-yl) -4-phenethylamino-6-tri-fluoromethyl-thieno- [ 2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-phenethylamino-6-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-phenethylamino-5-methylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-phenethylamino-5, 6,7, 8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cyclopententiene- [2,3-d] -pyrimidine gives 2 - (pyridin-4-yl) -4-phenethylamino-5,6-cyclopententiene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-cycloheptyrene- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-phenethylamino-5,6-cyclohepteniene - [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-ethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-phenethylamino-6-ethylthieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-chlorothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-phenethylamino-6-chlorothieno- [2, 3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5-chloro-6-methylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-phenethylamino-5-chloro -6-methylthieno- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-nitrothieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-phenethylamino-6-nitrothien- [2, 3 -d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -5,6-dimethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-phenethylamino-5,6-dimethyl -thien- [2,3-d] -pyrimidine; with 4-chloro-2- (pyridin-4-yl) -6-trifluoromethylthieno- [2,3-d] -pyrimidine gives 2- (pyridin-4-yl) -4-phenethylamino-6-tri-fluoromethyl-thienen- [ 2,3-d] -pyrimidine. Example 5 A solution of 2- (imidazol-1-yl) -6-methyl-4- (3-nitrobenzylamino) -thieno- [2,3-d] -pyrimidine in methanol is hydrogenated in the presence of Raney nickel. The catalyst is filtered, and the solution is evaporated. Recrystallization gives 2- (imidazol-1-yl) -6-methyl-4- (3-aminobenzylamino) -thieno- [2,3-d] -pyrimidine. EXAMPLE 6 1 ml of freshly distilled acetaldehyde is added to a solution of 6 g of 2- (imidazol-1-yl) -6-methyl-4- (3-amino-benzylamino) -thieno- [2, 3-d] -pyrimidine and 0.5 g titanium tetrachloride in 100 ml of methanol. Subsequently 4 g sodium cyanoborohydride are added, and the mixture is stirred for 30 hours. Semi-concentrated hydrochloric acid is added, and the mixture is subjected to conventional work, giving 2- (imidazol-1-yl) -6-methyl-4- (3-N-ethylaminobenzylamino) -thieno- [2,3-d] - pyrimidine. Example 7 The following compounds were obtained analogously to Example 2 2- (Imidazol-1-yl) -5,6,7,8-tetrahydro-4- (3,4-di-fluorobenzylamino) - [1] -benzylthiene - [2,3-d] -pyrimidine, mp 212 °; 2- (Imidazol-1-yl) -5,6-cyclopentene-4-benzylamino-thieno- [2,3-d] -pyrimidine, m.p. 221 °; 2- (Imidazol-1-yl) -6-methyl-4-benzylaminothieno- [2,3-d] -pyrimidine, m.p. 241 °; 2- (Imidazol-1-yl) -6-methyl-4- (3,4-dimethoxybenzylamino) -thieno- [2,3-d] -pyrimidine, m.p. 217 °; 2- (Imidazol-1-yl) -6-chloro-5-methyl-4- (3,4-methylene-dioxybenzylamino) -thieno- [2,3-d] -pyrimidine, m.p. 250 °; 2- (Imidazol-1-yl) -5,6,7,8-tetrahydro-4-benzylamino- [1] -benzylthieno- [2,3-d] -pyrimidine, m.p. 190 °; 2- (1,2,4-triazol-1-yl) -6-methyl-4- (3,4-methylenedioxy-benzylamino) -thieno- [2,3-d] -pyrimidine, m.p. 231 °; 2- (Imidazol-1-yl) -6-isopropyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine, m.p. 192 °; 2- (Imidazol-1-yl) -6-propyl-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine, m.p. 183 °. Example 8 The following compounds were obtained analogously to Example 2 2- (Morpholin-4-yl) -4- (3,4-methylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthien- [ 2,3-d] -pyrimidine, mp 175 °; 2- (Morpholin-4-yl) -4- (3,4-methylenedioxybenzylamino) -5,6-dimethylthieno- [2,3-d] -pyrimidine, m.p. 140 °; 2- (Morpholin-4-yl) -4- (3-chloro-4-methoxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine, 2- (Morpholin-4-yl) -4- (3-chloro-4-methoxybenzylamino) -5,6-dimethylthieno- [2,3-d] -pyrimidine, 2- (Morpholin-4-yl) -4- (3 , 4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine, 2- (Morpholin-4-yl) -4- (3,4-methylenedioxybenzylamino) -6-ethylthieno- [2,3-d] - pyrimidine, mp 217 °; 2- (4-Methyl-piperazin-1-yl) -4- (3,4-methylenedioxy-benzylamino) -6-ethylthieno- [2,3-d] -pyrimidine, m.p. 213 °; 2- (4-Methyl-piperazin-1-yl) -4- (3,4-methylenedioxybenzylamino) -5,6-dimethylthieno- [2,3-d] -pyrimidine, 2- [4- (2-hydroxyethyl) -piperazin-1-yi] -4- (3, 4-methylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno- [2,3-d] -pyrimidine, mp 243 °; 2- (4-Hydroxy-piperidin-1-yl) -5,6-cyclopentene-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine, m.p. 136-138 °; 2- [4- (2-Hydroxyethyl) -piperazin-1-yl] -5,6-cyclo-penten-4- (3,4-methylenedioxybenzylamino) -thieno- [2,3-d] -pyrimidine, 241 ° with decomposition; 2- [4- (2-Hydroxyethyl) -piperazin-1-yl] -4- (3-chloro-4-methoxybenzylamino) -5,6-dimethylthieno- [2,3-d] -pyrimidine, m.p. 274 ° Results of pharmacological tests.

It is noted that in relation to this date, the best method known to the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention.

Claims (6)

2. Having described the invention as above, the content of the following claims is claimed as property: 1. The use of compounds of formula I wherein R1, R2 each independently denote H, A, OA, alkenyl, alkynyl, N02, CF3 or Hal, R1, and R2 together also denote alkylene having
3. 3-5 atoms of C, R3, R4 each, independently of each other denote H, A, OA, OH, Hal, N02, NH2, NHA or NAA ', R3, and R4 together also denote -0-CH2-CH2- , -0-CH2-0-u -0-CH2-CH2-0-, A, A 'each, independently of each other, denote alkyl having from 1 to 6 carbon atoms, wherein 1-5 H atoms also can be replaced by F and / or chlorine, X denotes a 5-7 membered saturated heterocycle having 1-4 N, O and / or S atoms, linked N or C pathways, which is unsubstituted or mono-, di- - or trisubstituted by A, Hal or CF3, or morpholinyl,
4. 4-Y-piperidin-1-yl or 4-Y-piperazin-1-yl, Y denotes H, A, OH, -CH2OH or -CH2CH2OH, Hal denotes F , Cl, Br or I and n denotes 0, 1, 2 or 3, and pharmaceutically useful derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and / or modulation of the transduction of the kinase signal plays a role. 2. The use according to claim 1 of compounds of formula I in which X denotes morpholinyl, 4-y-piperidin-1-yl, 4-Y-piperazin-1-yl, 1-, 2-, 4- or
5. 5-imidazolyl, 2-methyl-l-imidazol-1-yl, 1-, 3-, 4- or 5-pyrazolyl, 2- 3 or 4-pyridyl, 2 -, 4, 5 or 6 pyrimidinyl, 1, 2, 3-triazol-l-, -4- or -5-yl, 1, 2,4-triazol-l-, -3- or 5-yl, 3- or 4-pyridazinyl or pyrazinyl, R1, R2 each, independently from each other, denote H, Hal or A, R1 and R2 together denote alkylene having 3-5 C atoms, R3, R4 each independently of each other, denote H, OA, OH or Hal, R3 and Rjuntos denote -0-CH2-CH2-, -0-CH2-0- or -0-CH2-CH2-0, Y denotes H, A, OH, -CH20H or -CH2CH20H, and derivatives, solvates, salts and stereoisomers thereof pharmaceutically useful, including mixtures thereof in all ratios. 3. The use according to claim 1 of compounds selected from the group (a) 2- (1-imidazolyl) -
6. 6-methyl-4- (3,4-methylenedioxybenzylamino) thieno [2,3-d] pyrimidine; (b) 2- (1-imidazolyl) -5,6-dimethyl-4- (3,4-methylene-dioxybenzylamino) thieno [2,3-d] pyrimidine; (c) 2- (1-imidazolyl) -4- (3,4-methylenedioxybenzylamine) -5,6,7,8-tetrahydro- [1] -benzylthieno [2,3-d] pyrimidine; (d) 2- (1-imidazolyl) -5-chloro-4- (3,4-methylenedioxybenzylamino) thieno [2,3-d] pyrimidine; (e) 2- (1-imidazolyl) -6-chloro-4- (3,4-methylenedioxybenzylamino) thieno [2,3-d] pyrimidine; (f) 2- (1,2,4-triazol-1-yl) -4- (3,4-methylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno [2, 3-d irimidine; (g) 2- (pyrazol-1-yl) -4- (3,4-methylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno [2,3-d] pyrimidine; (h) 2- (pyridin-3-yl) -4- (3,4-methylenedioxybenzylamine) -5,6,7,8-tetrahydro- [1] -benzylthieno [2,3-d] pyrimidine; (i) 2- (morpholin-4-yl) -4- (3,4-methylenedioxybenzylamino) -5,6,7,8-tetrahydro- [1] -benzylthieno [2,3-d] pyrimidine; (j) 2- (morpholin-4-yl) -4- (3,4-methylenedioxybenzylamino) -5,6-dimethylthieno [2,3-d] pyrimidine, solvates, salts and stereoisomers thereof pharmaceutically useful, including mixtures of them in all relationships. 4. The use according to claim 1, 2 or 3, wherein the kinases are selected from the group of the pyrimines kinases and Raf kinases. 5. The use according to claim 4, wherein the tyrosine kinases are TIE-2, VEGFR, PDGFR, FGFR, and / or FLT / KDR. The use according to claim 4 of compounds according to claim 1, and pharmaceutically useful derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases that are influenced by the inhibition of the torosine kinases by the compounds according to claim 1. The use according to claim 6 for the preparation of a medicament for the treatment of diseases that are influenced by the inhibition of TIE-2, VEGFR, PDGFR, FGFR and / or FLT / KDR by the compounds according to claim 1. 8. The use according to claim 6 or 7, wherein the Disease to be treated is a solid tumor. The use according to claim 8, wherein the solid tumor originates from the group of squamous epithelium tumors, bladder, stomach, kidneys, head and neck, esophagus, cervix, thyroid, intestine, liver, brain, prostate, tract urogenital, lymphatic system, stomach, larynx and / or lung. 10. The use according to claim 8, wherein the solid tumor originates from the group of monocytic leukemia, lung adenocarcinoma, small cell lung carcinomas, pancreatic cancer, gliblastomas and breast carcinoma. The use according to claim 8, wherein the solid tumor originates from the group of lung adenocarcinoma, small cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma. 12. The use according to claim 6 or 7, wherein the disease to be treated is a tumor of the blood and immune system. 13. The use according to claim 12, wherein the tumor originates from the group of acute myocytic leukemia, chronic myelocytic leukemia, acute lymphatic leukemia and / or chronic lymphatic leukemia. 14. The use according to claim 6 or 7, for the treatment of a disease in which angiogenesis is involved. 15. The use according to claim 14, wherein the disease is an ocular disease. 16. The use according to claim 6 or 7, for the treatment of retinal vascularization, diabetic retinopathy, macular degeneration induced by age and / or inflammatory diseases. 17. The use according to claim 16, wherein the inflammatory disease originates from the group of rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reaction. 18. The use according to claim 6 or 7, for the treatment of bone pathologies, where the bone pathology originates from the group of osteosarcoma, osteoarthritis and rickets. The use of compounds of formula I according to claim 1 and / or the pharmaceutically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumors, wherein a therapeutically effective amount of a compound is administered of formula I in combination with a compound of group 1) an estrogen receptor modulator, 2) an androgen receptor modulator, 3) a retinoid receptor modulator, 4) a cytotoxic agent, 5) an antiproliferative agent, 6) a prenyl protein transferase inhibitor, 7) in HMG-CoA reductase inhibitor, 8) an HIV protease inhibitor, 9) a reverse transcriptase inhibitor and 10) another angiogenesis inhibitor. The use of compounds of formula I according to claim 1 and / or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumors, wherein a therapeutically effective amount of a compound is administered. of formula I in combination with radiotherapy and a compound of group 1) an estrogen receptor modulator, 2) an androgen receptor modulator, 3) a retinoid receptor modulator, 4) a cytotoxic agent, 5) an antiproliferative agent, ) an inhibitor of prenyl protein transferase, 7) an inhibitor of HMG-CoA reductase, 8) an inhibitor of HIV protease, 9) a reverse transcriptase inhibitor and 10) another inhibitor of angiogenesis. The use according to claim 6 or 7 for the preparation of a medicament for the treatment of diseases that are based on disturbed TIE-2 activity, wherein a therapeutically effective amount of a compound according to claim 1 is administered in combination with a growth factor receptor inhibitor. 22. The use according to claim 1, 2, 3 or 4 of compounds of formula I for the preparation of a medicament for the treatment of diseases that are caused, mediated and / or propagated by Raf kinases. 23. The use according to claim 22, wherein the Raf kinase is selected from the group consisting of A-Raf, B-Raf, and Raf-1. 24. The use according to claim 22, wherein the diseases are selected from the group of hyperproliferative and non-hyperproliferative diseases. 25. The use according to claim 22 or 24, wherein the disease is cancerous. 26. The use according to claim 22 or 24, wherein the disease is not cancerous. 27. The use according to claim 22, 24 or 26 where the non-cancerous diseases are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, benign prostatic hyperplasia, immunological diseases, uatoinmune diseases and immunodeficiency diseases. The use according to claim 22, 24 or 25, wherein the non-cancerous diseases are selected from the group consisting of brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, liver cancer, kidney cancer, colorectal cancer, breast cancer, head cancer, neck cancer, esophageal cancer, gynecological cancer, thyroid cancer, lymphoma, chronic leukemia and acute leukemia. 29. Compounds of formula I characterized in that R1, R2 each independently denote H, A, OA, alkenyl, alkynyl, N02, CF3 or Hal, R1, R2 together also denote alkylene having 3-5 C atoms, R3, R4 each, independently of each other they denote H, A, OA, OH, Hal, N02, NH2, NHA or NAA ', R3, and R4 together also denote -0-CH2-CH2- ,. -0-CH2-0-u -0-CH2-CH2-0-, A, A 'each, independently of each other, denote alkyl having from 1 to 6 carbon atoms, wherein 1-5 H atoms can also to be replaced by F and / or chloro, X denotes morpholinyl, 4-Y-piperidin-1-yl or 4-Y-piperazin-1-yl, and denotes H, A, OH, -CH 2 OH or -CH 2 CH 2 OH, Hal denotes F , Cl, Br or I and n denotes 0, 1, 2 or 3, and pharmaceutically useful derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios. 30. The compounds according to claim 29, characterized in that X denotes morpholinyl, 4-Y-piperidin-1-yl or 4-Y-piperazin-1-yl, R 1, R each, independently of each other, denote H, Hal or A, R1 and R2 denote alkylene together having 3-5 C atoms, R3, R4 each, independently of each other, denote H, OA, OH or Hal, R3 and R4 together denote -0-CH2-CH2- , -0-CH2-0- or -O-CH2-CH2-0, and pharmaceutically useful derivatives, solvates, and stereoisomers thereof, including mixtures thereof in all ratios. 31. Medicaments, characterized in that they comprise at least one compound of formula I according to claim 29 or 30 and / or pharmaceutically useful derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and / or adjuvants. SUMMARY OF THE INVENTION The compounds of formula (I) in which R1 and R2, R3, and R4 X and n have the meanings indicated in claim (1), are inhibitors of tyrosine kinases, in particular of the TIE-2 kinases, and Raf and can be employees, inter alia, for the treatment of tumors.